You are on page 1of 47

Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Relationship Between
Platinum Levels in the Allocation: Non-
Drug: oxaliplatin|Procedure: Groupe Cooperateur
Blood and Neurotoxicity in Randomized|Masking:
233 NCT00274885 Recruiting management of therapy Multidisciplinaire en Phase IV 58 10-Jan-06 Oct-05 6-Feb-09 May-07
Patients Who Are Receiving Open Label|Primary
complications Oncologie (GERCOR)
Oxaliplatin for Purpose: Treatment
Gastrointestinal Cancer

Fluorouracil With or
European Allocation:
Without Cisplatin in
Active, not Organization for Randomized|Control:
7 NCT00003029 Treating Patients With Drug: cisplatin|Drug: fluorouracil Phase III 200 1-Nov-99 May-97 23-Jul-08 Oct-02
recruiting Research and Active Control|Primary
Advanced or Metastatic
Treatment of Cancer Purpose: Treatment
Cancer of the Pancreas

Surgery Followed by
Drug: fluorouracil|Drug: Allocation:
Radiation Therapy and Mayo Clinic|National
Active, not leucovorin calcium|Procedure: Randomized|Control:
32 NCT00003049 Chemotherapy in Treating Cancer Institute Phase III 100 1-Nov-99 May-97 6-Feb-09 Sep-03
recruiting conventional surgery|Radiation: Active Control|Primary
Patients With Cancer of the (NCI)
radiation therapy Purpose: Treatment
Pancreas

North Central Cancer


Allocation:
Glutamine in Preventing Treatment
Active, not Randomized|Primary
46 NCT00003170 Acute Diarrhea in Patients Dietary Supplement: glutamine Group|National Phase III 120 1-Nov-99 Feb-98 6-Feb-09 May-07
recruiting Purpose: Supportive
With Pelvic Cancer Cancer Institute
Care
(NCI)

Radiation Therapy
Oncology
Group|National
Fluorouracil, Gemcitabine, Drug: fluorouracil|Drug: Allocation:
Cancer Institute
and Radiation Therapy in gemcitabine Randomized|Control:
11 NCT00003216 Completed (NCI)|Eastern Phase III 518 1-Nov-99 Jul-98 28-Mar-09 Apr-03 Mar-08
Treating Patients With hydrochloride|Radiation: Active Control|Primary
Cooperative
Cancer of the Pancreas radiation therapy Purpose: Treatment
Oncology
Group|Southwest
Oncology Group

Gemcitabine With or
Without R115777 in Allocation:
Active, not Drug: gemcitabine Janssen
19 NCT00005648 Treating Patients With Phase III Randomized|Primary 2-May-00 Nov-99 23-Jul-08 Jun-07
recruiting hydrochloride|Drug: tipifarnib Pharmaceuticals
Advanced Pancreatic Purpose: Treatment
Cancer

Nitrocamptothecin
Compared With
Gemcitabine in Treating Allocation:
Active, not Drug: gemcitabine
21 NCT00005869 Patients With Unresectable SuperGen Phase III Randomized|Primary 2-Jun-00 Nov-98 23-Jul-08 Jun-07
recruiting hydrochloride|Drug: rubitecan
Locally Advanced or Purpose: Treatment
Metastatic Pancreatic
Cancer

Nitrocamptothecin or
Fluorouracil in Treating Allocation:
Active, not Drug: fluorouracil|Drug:
25 NCT00005871 Patients With Recurrent or SuperGen Phase III Randomized|Primary 2-Jun-00 Nov-98 23-Jul-08 Jun-07
recruiting rubitecan
Refractory Pancreatic Purpose: Treatment
Cancer

1 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Nitrocamptothecin
Compared With Other
Drug: fluorouracil|Drug: Allocation:
Chemotherapy in Treating Active, not
26 NCT00005870 gemcitabine hydrochloride|Drug: SuperGen Phase III Randomized|Primary 2-Jun-00 Mar-99 23-Jul-08 Jun-07
Patients With Recurrent or recruiting
mitomycin C|Drug: rubitecan Purpose: Treatment
Refractory Cancer of the
Pancreas

Vapreotide in Treating
Mayo Clinic|National
Patients Undergoing Active, not Drug: vapreotide|Procedure: Primary Purpose:
39 NCT00014651 Cancer Institute Phase III 10-Apr-01 Mar-01 9-May-09 Aug-06
Elective Pancreatic recruiting conventional surgery Supportive Care
(NCI)
Resection

Ondansetron With or Allocation:


Without Dexamethasone to Randomized|Control:
Drug: dexamethasone|Drug:
Prevent Vomiting in NCIC Clinical Trials Placebo Control|Masking:
44 NCT00016380 Completed ondansetron|Procedure: quality- Phase III 6-May-01 Feb-01 Feb-09 5-Mar-10 Mar-10
Patients Receiving Group Double-Blind|Primary
of-life assessment
Radiation Therapy to the Purpose: Supportive
Upper Abdomen Care

Triacetyluridine and
Fluorouracil Compared Allocation:
With Gemcitabine in Drug: fluorouracil|Drug: Randomized|Control:
Active, not
22 NCT00024427 Treating Patients With gemcitabine hydrochloride|Drug: Wellstat Therapeutics Phase III Active Control|Masking: 13-Sep-01 Feb-01 9-May-09 May-05
recruiting
Unresectable Locally triacetyluridine Open Label|Primary
Advanced, or Metastatic Purpose: Treatment
Pancreatic Cancer

Gemcitabine With or
Allocation:
Without Exatecan Mesylate
Randomized|Control:
in Treating Patients With Active, not Drug: exatecan mesylate|Drug:
13 NCT00023972 Daiichi Sankyo Inc. Phase III Active Control|Masking: 13-Sep-01 Jul-01 23-Jul-08 Nov-02
Locally Advanced or recruiting gemcitabine hydrochloride
Open Label|Primary
Metastatic Pancreatic
Purpose: Treatment
Cancer

Gemcitabine With or
Without Erlotinib in
Drug: erlotinib
Treating Patients With NCIC Clinical Trials Primary Purpose:
28 NCT00026338 Completed hydrochloride|Drug: gemcitabine Phase III 9-Nov-01 Aug-01 Feb-09 5-Mar-10 Mar-10
Unresectable Locally Group Treatment
hydrochloride
Advanced or Metastatic
Pancreatic Cancer

Swiss Group for


Gemcitabine With or
Clinical Cancer Allocation:
Without Capecitabine in
Active, not Drug: capecitabine|Drug: Research|Central Randomized|Control:
1 NCT00030732 Treating Patients With Phase III 14-Feb-02 Jun-01 13-Aug-08 Aug-08
recruiting gemcitabine hydrochloride European Active Control|Primary
Advanced Pancreatic
Cooperative Purpose: Treatment
Cancer
Oncology Group

Gemcitabine With or
Allocation:
Without Capecitabine in
Randomized|Control:
Treating Patients With Drug: capecitabine|Drug:
18 NCT00032175 Completed Cancer Research UK Phase III 508 Active Control|Masking: 8-Mar-02 Apr-02 13-Jan-10 Apr-07
Locally Advanced or gemcitabine hydrochloride
Open Label|Primary
Metastatic Pancreatic
Purpose: Treatment
Cancer

Gemcitabine With or
Drug: dalteparin|Drug: University of Allocation:
Without Dalteparin in
gemcitabine Rochester|National Randomized|Control:
30 NCT00031837 Treating Patients With Completed Phase III 400 8-Mar-02 Oct-02 19-Aug-09 Jan-07
hydrochloride|Procedure: quality- Cancer Institute Active Control|Primary
Unresectable or Metastatic 2 of 47 4/20/2010, 8:16 PM
of-life assessment (NCI) Purpose: Treatment
Pancreatic Cancer
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Irofulven Compared With


Fluorouracil in Treating Active, not Drug: fluorouracil|Drug: Primary Purpose:
6 NCT00033735 Eisai Inc. Phase III 9-Apr-02 Jan-00 23-Jul-08 Jun-02
Patients With Pancreatic recruiting irofulven Treatment
Cancer

Allocation:
Randomized|Control:
A Phase 3 Trial of ALIMTA Active Control|Endpoint
(LY231514, Pemetrexed) Classification:
Plus GEMZAR Versus Safety/Efficacy
52 NCT00035035 Completed Drug: GEMZAR|Drug: ALIMTA Eli Lilly and Company Phase III 2-May-02 18-Jul-06 Jul-06
GEMZAR in Patients With Study|Intervention
Unresectable or Metastatic Model: Parallel
Cancer of the Pancreas. Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
A Study to Test the
Active Control|Endpoint
Effectiveness of
Classification: Efficacy
Virulizin® Given in
63 NCT00040092 Completed Drug: Virulizin® Lorus Therapeutics Phase III 400 Study|Intervention 19-Jun-02 Jul-02 4-Jan-08 Jan-08 Jul-05
Combination With
Model: Parallel
Standard Chemotherapy
Assignment|Masking:
for Pancreatic Cancer
Double-Blind|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
OSI-774 (Tarceva) Plus Placebo Control|Endpoint
OSI
Gemcitabine in Patients Classification: Efficacy
Drug: Tarceva (erlotinib HCl, Pharmaceuticals|NCI
71 NCT00040183 With Locally Advanced, Completed Phase III 500 Study|Intervention 21-Jun-02 Oct-01 Sep-04 25-Jan-06 Jan-06
OSI-774) C Clinical Trials
Unresectable or Metastatic Model: Parallel
Group
Pancreatic Cancer. Assignment|Masking:
Double-Blind|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Placebo Control|Endpoint
Safety and Efficacy of Classification:
G17DT Immunogen in the Active, not Safety/Efficacy
85 NCT00044031 Drug: G17DT Immunogen Aphton Phase III 16-Aug-02 Feb-01 23-Jun-05 Mar-03
Treatment of Advanced recruiting Study|Intervention
Pancreatic Carcinoma Model: Parallel
Assignment|Masking:
Double-Blind|Primary
Purpose: Treatment

3 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Gemcitabine With or
Dietary Supplement: Allocation:
Without Pemetrexed Ireland Cancer
cyanocobalamin|Dietary Randomized|Control:
Disodium in Treating Active, not Center|National
2 NCT00049426 Supplement: folic acid|Drug: Phase III Active Control|Masking: 12-Nov-02 Jul-02 6-Feb-09 Mar-03
Patients With Unresectable recruiting Cancer Institute
gemcitabine hydrochloride|Drug: Open Label|Primary
Stage II, Stage III, or (NCI)
pemetrexed disodium Purpose: Treatment
Stage IV Pancreatic Cancer

A Study of TNFeradeâ„¢ Allocation:


Biologic With 5-FU and Randomized|Endpoint
Radiation Therapy for First- Classification:
Active, not
56 NCT00051467 Line Treatment of Genetic: TNFerade GenVec Phase III Safety/Efficacy 10-Jan-03 31-Mar-10 Mar-10
recruiting
Unresectable Locally Study|Masking: Open
Advanced Pancreatic Label|Primary Purpose:
Cancer Treatment

Royal Liverpool
Two Chemotherapy
University
Regimens Compared With Drug: fluorouracil|Drug: Allocation:
Hospital|NCIC Clinical
Observation in Treating Active, not gemcitabine hydrochloride|Drug: Randomized|Control:
23 NCT00058201 Trials Phase III 1030 7-Apr-03 Jul-01 13-Dec-09 May-08 Apr-08
Patients With Completely recruiting leucovorin calcium|Other: Active Control|Primary
Group|Australasian
Resected Pancreatic clinical observation Purpose: Treatment
Gastro-Intestinal
Cancer
Trials Group

Gemcitabine With or
Eastern Cooperative
Without Oxaliplatin in Allocation:
Oncology
Treating Patients With Drug: gemcitabine Randomized|Control:
24 NCT00058149 Completed Group|National Phase III 7-Apr-03 Mar-03 11-Jul-09 Apr-04 Jul-06
Locally Advanced or hydrochloride|Drug: oxaliplatin Active Control|Primary
Cancer Institute
Metastatic Pancreatic Purpose: Treatment
(NCI)
Cancer

Eastern Cooperative
Oncology
Gemcitabine With or Allocation:
Drug: gemcitabine Group|National
Without Radiation Therapy Randomized|Control:
9 NCT00057876 Completed hydrochloride|Radiation: Cancer Institute Phase III 7-Apr-03 Apr-03 29-May-09 Jan-06 May-09
in Treating Patients With Active Control|Primary
radiation therapy (NCI)|Radiation
Pancreatic Cancer Purpose: Treatment
Therapy Oncology
Group

Gemcitabine With or
Without Oxaliplatin in Allocation:
Groupe Cooperateur
Treating Patients With Active, not Drug: gemcitabine Randomized|Control:
31 NCT00075452 Multidisciplinaire en Phase III 9-Jan-04 Nov-03 23-Jul-08 May-07
Locally Advanced or recruiting hydrochloride|Drug: oxaliplatin Active Control|Primary
Oncologie (GERCOR)
Metastatic Unresectable Purpose: Treatment
Pancreatic Adenocarcinoma

Gemcitabine With or Southwest Oncology


Without Cetuximab as First- Group|National Allocation:
Line Therapy in Treating Cancer Institute Randomized|Control:
Active, not Biological: cetuximab|Drug:
16 NCT00075686 Patients With Locally (NCI)|Cancer and Phase III Active Control|Masking: 9-Jan-04 Jan-04 6-Feb-09 Aug-06
recruiting gemcitabine hydrochloride
Advanced Unresectable or Leukemia Group Open Label|Primary
Metastatic Adenocarcinoma B|NCIC Clinical Trials Purpose: Treatment
of the Pancreas Group

4 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation: Non-
Randomized|Control:
Esomeprazole In Patients
Uncontrolled|Endpoint
With Gastric Acid
Classification: Efficacy
Hypersecretory States
105 NCT00079833 Completed Drug: Esomeprazole magnesium AstraZeneca Phase III 25 Study|Intervention 16-Mar-04 Jul-03 Jul-05 25-Mar-09 Mar-09
Including Idiopathic
Model: Single Group
Hypersecretion and
Assignment|Masking:
Zollinger-Ellison Syndrome
Open Label|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
PANVACâ„¢-VF Vaccine for Active Control|Endpoint
the Treatment of Classification:
Metastatic Pancreatic Active, not Therion Biologics Safety/Efficacy
54 NCT00088660 Biological: PANVACâ„¢-VF Phase III 250 30-Jul-04 Jun-04 7-Feb-06 Feb-06
Cancer After Failing a recruiting Corporation Study|Intervention
Gemcitabine-Containing Model: Single Group
Regimen Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Gemcitabine With or
Allocation:
Without Bevacizumab in Cancer and Leukemia
Randomized|Control:
Treating Patients With Active, not Biological: bevacizumab|Drug: Group B|National
5 NCT00088894 Phase III Placebo Control|Masking: 4-Aug-04 Jun-04 25-Jul-09 Apr-06
Locally Advanced or recruiting gemcitabine hydrochloride Cancer Institute
Double-Blind|Primary
Metastatic Pancreatic (NCI)
Purpose: Treatment
Cancer

Allocation:
Randomized|Control:
Study of the Efficacy and Uncontrolled|Endpoint
Safety of Glufosfamide Classification:
Compared With Best Threshold Safety/Efficacy
33 NCT00099294 Completed Drug: Glufosfamide Phase III 300 10-Dec-04 Sep-04 Jan-07 28-Apr-09 Apr-09 Jan-07
Supportive Care in Pharmaceuticals|PPD Study|Intervention
Metastatic Pancreatic Model: Parallel
Cancer Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Memorial Sloan-
An Analysis of the
Radiation: Ionizing radiation (IR) Kettering Cancer Observational Model:
Response of Human Tumor Active, not
206 NCT00132704 therapy|Radiation: Ionizing Center|National Phase III 149 Cohort|Time Perspective: 18-Aug-05 Aug-04 Aug-10 14-Aug-09 Aug-09 Aug-10
Microvascular Endothelium recruiting
radiation (IR) Cancer Institute Prospective
to Ionizing Radiation
(NCI)

Allocation:
Randomized|Control:
Placebo Control|Endpoint
Memorial Sloan- Classification: Efficacy
Acupuncture For Pancreatic
10 NCT00136669 Completed Procedure: Acupuncture Kettering Cancer Phase III 60 Study|Intervention 25-Aug-05 Sep-03 Sep-05 7-Sep-06 Sep-06
Cancer Pain
Center Model: Parallel
Assignment|Masking:
Single Blind|Primary
Purpose: Treatment

5 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation:
Acute Normovolemic Randomized|Endpoint
Hemodilution Versus Classification: Efficacy
Standard Intraoperative Procedure: Normovolemic Memorial Sloan- Study|Intervention
Active, not
255 NCT00200148 Management in Patients Hemodilution (ANH)|Procedure: Kettering Cancer Phase III 372 Model: Parallel 12-Sep-05 Mar-04 Mar-10 21-Oct-09 Oct-09 Mar-10
recruiting
Having Hepatic Resection Standard of care Center Assignment|Masking:
and Single Blind
Pancreaticoduodenectomy (Subject)|Primary
Purpose: Treatment

Gemcitabine and
Groupe Cooperateur Allocation:
Oxaliplatin in Treating Active, not Drug: gemcitabine
40 NCT00268411 Multidisciplinaire en Phase III 80 Randomized|Primary 20-Dec-05 Sep-04 23-May-08 May-07
Patients With Metastatic recruiting hydrochloride|Drug: oxaliplatin
Oncologie (GERCOR) Purpose: Treatment
Pancreatic Cancer

Allocation:
Randomized|Control:
Placebo Control|Endpoint
National Institute of
Randomized Trial of EUS Classification: Efficacy
Procedure: Celiac Plexus Diabetes and
51 NCT00279292 Neurolysis in Pancreas Completed Phase III 26 Study|Intervention 17-Jan-06 Aug-04 17-Mar-10 Mar-10
Neurolysis Digestive and Kidney
Cancer Model: Single Group
Diseases (NIDDK)
Assignment|Masking:
Double-Blind|Primary
Purpose: Treatment

Combination
Chemotherapy in Treating Drug: cisplatin|Drug:
Fondation Francaise Allocation:
Patients With Metastatic fluorouracil|Drug: gemcitabine
41 NCT00303758 Completed de Cancerologie Phase III 202 Randomized|Primary 15-Mar-06 Oct-05 21-Nov-09 Dec-06
Pancreatic Cancer That hydrochloride|Drug: leucovorin
Digestive Purpose: Treatment
Cannot Be Removed By calcium
Surgery

Allocation:
Randomized|Endpoint
Classification:
Effects Of Nadroparin In
Safety/Efficacy
Patients With Lung,
58 NCT00312013 Completed Drug: Nadroparin GlaxoSmithKline Phase III 503 Study|Intervention 5-Apr-06 May-06 Jul-09 15-Apr-10 Apr-10 Jul-09
Pancreas Or Prostate
Model: Parallel
Cancer
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Allocation:
Pharmexa A/S|ICON
Randomized|Control:
Clinical
GV1001 and Gemcitabine Active Control|Endpoint
Research|ORION
in Sequential Combination Classification: Efficacy
Biological: GV1001|Drug: Clinical
14 NCT00358566 to Gemcitabine Terminated Phase III 360 Study|Intervention 14-Jul-06 Jun-06 Aug-08 16-May-08 May-08 Aug-08
Gemcitabine (Chemotherapy) Services|CIRION
Monotherapy in Pancreatic Model: Parallel
Central
Cancer Assignment|Masking:
Laboratory|Dorevitch
Open Label|Primary
|Kendle International
Purpose: Treatment

6 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation:
Randomized|Control:
Placebo Control|Endpoint
Study of Lanreotide Classification: Efficacy
Autogel in Non-functioning Drug: lanreotide (Autogel Study|Intervention
59 NCT00353496 Recruiting Ipsen Phase III 200 17-Jul-06 Jun-06 Jun-12 8-Mar-10 Mar-10 Jun-12
Entero-pancreatic formulation)|Other: Placebo Model: Parallel
Endocrine Tumours Assignment|Masking:
Double Blind (Subject,
Investigator)|Primary
Purpose: Treatment

Counseling and Nicotine Fox Chase Cancer


Allocation:
Replacement Therapy in Center|National
45 NCT00365508 Completed Drug: nicotine Phase III 700 Randomized|Masking: 16-Aug-06 Feb-06 5-Nov-09 Nov-09 Aug-09
Helping Adult Smokers Cancer Institute
Open Label
Quit Smoking (NCI)

Control:
Uncontrolled|Endpoint
A Open-label Study to Classification:
Assess the Safety of Oral Safety/Efficacy
Active, not Solvay
279 NCT00401076 Long-term Use of SA-001 Drug: SA-001 Phase III 80 Study|Intervention 16-Nov-06 Jan-08 Nov-10 1-Apr-10 Apr-10 Nov-10
recruiting Pharmaceuticals, Inc.
in Pancreatic Exocrine Model: Single Group
Insufficiency Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Gemcitabine With or
Without Combination
Chemotherapy and Federation
Drug: cisplatin liposomal|Drug: Allocation:
Radiation Therapy in Active, not Francophone de
38 NCT00416507 fluorouracil|Drug: gemcitabine Phase III 190 Randomized|Primary 27-Dec-06 23-Jul-08 May-08
Treating Patients With recruiting Cancerologie
hydrochloride Purpose: Treatment
Nonmetastatic Pancreatic Digestive
Cancer That Cannot Be
Removed By Surgery

Allocation:
Larotaxel Compared To Randomized|Control:
Continuous Administration Active Control|Endpoint
of 5-FU in Advanced Classification: Efficacy
Drug: larotaxel
72 NCT00417209 Pancreatic Cancer Patients Completed Sanofi-Aventis Phase III 400 Study|Intervention 28-Dec-06 Dec-06 Nov-09 18-Dec-09 Dec-09 Jul-09
(XRP9881)|Drug: 5-Fluorouracil
Previously Treated With A Model: Parallel
Gemcitabine-Containing Assignment|Masking:
Regimen Open Label|Primary
Purpose: Treatment

Gemcitabine and
Biological:
Capecitabine With or Allocation:
sargramostim|Biological:
Without Vaccine Therapy in Randomized|Control:
telomerase peptide vaccine Royal Liverpool
17 NCT00425360 Treating Patients With Recruiting Phase III 1110 Active Control|Masking: 19-Jan-07 Sep-06 23-Dec-09 May-09
GV1001|Drug: University Hospital
Locally Advanced or Open Label|Primary
capecitabine|Drug: gemcitabine
Metastatic Pancreatic Purpose: Treatment
hydrochloride
Cancer

7 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation: Non-
Randomized|Endpoint
A Continuation Study Using
Classification: Safety
Sunitinib Malate For
Active, not Study|Intervention
125 NCT00428220 Patients Leaving Treatment Drug: sunitinib Pfizer Phase III 300 26-Jan-07 Jul-07 May-14 6-Apr-10 Apr-10 May-14
recruiting Model: Single Group
On A Previous Sunitinib
Assignment|Masking:
Study.
Open Label|Primary
Purpose: Treatment

Allocation:
Randomized|Endpoint
Classification:
A Study Of Sunitinib
Safety/Efficacy
Compared To Placebo For
Drug: sunitinib malate|Drug: Study|Intervention
80 NCT00428597 Patients With Advanced Terminated Pfizer Phase III 171 29-Jan-07 Mar-07 Apr-09 14-Jul-09 Jul-09 Apr-09
Placebo Model: Parallel
Pancreatic Islet Cell
Assignment|Masking:
Tumors
Double Blind (Subject,
Investigator)|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Uncontrolled|Endpoint
Capecitabine/Erlotinib
Ludwig-Maximilians - Classification:
Followed of Gemcitabine
Active, not Drug: gemcitabine|Drug: University of Safety/Efficacy
15 NCT00440167 Versus Phase III 22-Feb-07 Jun-06 22-Oct-09 Oct-09
recruiting capecitabine|Drug: Erlotinib Munich|Roche Study|Intervention
Gemcitabine/Erlotnib
Pharma AG Model: Crossover
Followed of Capecitabine
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Allocation:
Randomized|Endpoint
Classification:
Study Of Gemcitabine Plus Safety/Efficacy
Drug: AG-013736|Drug:
AG-013736 Versus Active, not Study|Intervention
29 NCT00471146 Gemcitabine|Drug: Pfizer Phase III 632 7-May-07 Aug-07 Sep-10 2-Apr-10 Apr-10 Jan-09
Gemcitabine For Advanced recruiting Model: Parallel
Gemcitabine|Drug: placebo
Pancreatic Cancer. Assignment|Masking:
Double Blind (Subject,
Investigator)|Primary
Purpose: Treatment

Other: counseling
intervention|Procedure:
Electronic Tool to Record Allocation:
cognitive assessment|Procedure:
Cancer Symptoms in Swiss Group for Randomized|Control:
fatigue assessment and
37 NCT00477919 Patients With Advanced Recruiting Clinical Cancer Phase III 192 Active Control|Primary 23-May-07 Feb-07 30-Oct-09 Jul-09 Jun-10
management|Procedure:
Cancer Receiving Palliative Research Purpose: Health Services
psychosocial assessment and
Care Research
care|Procedure: quality-of-life
assessment

8 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation:
Phase III Trial of
Randomized|Control:
Gemcitabine, Curcumin
Placebo
and Celebrex in Patients Drug: Gemcitabine|Drug: Tel-Aviv Sourasky
4 NCT00486460 Recruiting Phase III Control|Intervention 13-Jun-07 Jun-05 13-Jun-07 Jun-07
With Advance or Curcumin|Drug: Celebrex Medical Center
Model: Parallel
Inoperable Pancreatic
Assignment|Masking:
Cancer
Double-Blind

Allocation:
Randomized|Control:
Active Control|Endpoint
Phase III of Gemcitabine Classification:
Taiho Pharmaceutical
Vs TS-1 Vs Gemcitabine Active, not Drug: Gemcitabine plus TS- Safety/Efficacy
34 NCT00498225 Co., Ltd.|TTY Phase III 750 6-Jul-07 Jul-07 Jun-13 28-Jan-10 Jan-10 Jun-12
Plus TS-1 in Pancreatic recruiting 1|Drug: TS-1|Drug: Gemcitabine Study|Intervention
Biopharm
Cancer Model: Parallel
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Allocation:
Randomized|Intervention
Efficacy and Safety of
Model: Parallel
Everolimus (RAD001) in
Assignment|Masking:
Female or Male Patients 18 Active, not Novartis
73 NCT00510068 Drug: RAD001 (Everolimus) Phase III 410 Double Blind (Subject, 31-Jul-07 Jul-07 18-Nov-09 Nov-09 Dec-10
Years or Older With recruiting Pharmaceuticals
Caregiver, Investigator,
Advanced Neuroendocrine
Outcomes
Tumors
Assessor)|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Fentanyl Sublingual Spray Drug: fentanyl sublingual
Insys Therapeutics Placebo Control|Masking:
47 NCT00538850 in Treating Patients With Recruiting spray|Other: questionnaire Phase III 130 1-Oct-07 Oct-07 9-Apr-10 Oct-08 Dec-08
Inc Double-Blind|Primary
Breakthrough Cancer Pain administration
Purpose: Supportive
Care

Gemcitabine With or
Allocation:
Without Sorafenib in
Drug: gemcitabine Randomized|Control:
Treating Patients With Institut Paoli-
27 NCT00541021 Recruiting hydrochloride|Drug: sorafenib Phase III 104 Placebo Control|Masking: 5-Oct-07 Dec-06 13-Dec-09 Jul-09 Dec-10
Locally Advanced or Calmettes
tosylate Double-Blind|Primary
Metastatic Pancreatic
Purpose: Treatment
Cancer

Allocation:
Randomized|Endpoint
Classification:
Safety/Efficacy
Management of
Massachusetts Study|Intervention
292 NCT00550108 Incidentally Discovered Terminated Other: Ethanol lavage Phase III 0 24-Oct-07 Oct-07 Oct-12 23-Jun-08 Jun-08 Oct-12
General Hospital Model: Parallel
Pancreatic Cysts
Assignment|Masking:
Double Blind (Subject,
Investigator)|Primary
Purpose: Treatment

9 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation:
Randomized|Control:
Placebo Control|Endpoint
Aflibercept Compared to Classification: Efficacy
Placebo in Term of Efficacy Sanofi- Study|Intervention
Active, not Drug: placebo|Drug: Aflibercept
69 NCT00574275 in Patients Treated With Aventis|Regeneron Phase III 630 Model: Parallel 14-Dec-07 Dec-07 Nov-10 15-Sep-09 Sep-09 Nov-10
recruiting (AVE0005)
Gemcitabine for Metastatic Pharmaceuticals Assignment|Masking:
Pancreatic Cancer Double Blind (Subject,
Caregiver,
Investigator)|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
S-1 Versus 5-FU Bolus in Active Control|Endpoint
Metastatic Pancreatic Sanofi-Aventis|Taiho Classification: Efficacy
Active, not
70 NCT00602745 Cancer Patients Previously Drug: S-1|Drug: 5-Fluorouracil Pharmaceutical Co., Phase III 400 Study|Intervention 16-Jan-08 Dec-07 Jun-10 7-Apr-09 Apr-09 Jun-10
recruiting
Treated With Gemcitabine- Ltd. Model: Parallel
Based Regimen Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Placebo Control|Endpoint
Treatment of Cancer- Classification:
Anorexia Using Megestrol Drug: Megestrol acetate Par Pharmaceutical, Safety/Efficacy
67 NCT00637728 Acetate Concentrated Terminated concentrated suspension 110 Inc.|PRA Phase III 5 Study|Intervention 11-Mar-08 Jun-06 Sep-06 11-Mar-08 Mar-08 Sep-06
Suspension in Lung or mg/mL|Drug: Placebo International Model: Parallel
Pancreatic Cancer Patients Assignment|Masking:
Double Blind (Subject,
Investigator)|Primary
Purpose: Treatment

Gemcitabine With or
Without Capecitabine
and/or Radiation Therapy Drug: capecitabine|Drug:
or Gemcitabine With or erlotinib hydrochloride|Drug:
Groupe Cooperateur Allocation:
Without Erlotinib in gemcitabine
12 NCT00634725 Recruiting Multidisciplinaire en Phase III 820 Randomized|Primary 12-Mar-08 Feb-08 2-Dec-09 Jul-09 May-11
Treating Patients With hydrochloride|Other: laboratory
Oncologie (GERCOR) Purpose: Treatment
Locally Advanced biomarker analysis|Radiation:
Pancreatic Cancer That radiation therapy
Cannot Be Removed by
Surgery

10 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation:
Randomized|Control:
Active Control|Endpoint
Classification:
Randomized Controlled Safety/Efficacy
Huazhong University
Trial of Gemcitabine Drug: gemcitabine|Other: 125I Study|Intervention
60 NCT00644618 Completed of Science and Phase III 120 24-Mar-08 Jan-03 Jan-08 24-Mar-08 Mar-08 Dec-07
Combined With 125I brachytherapy PLUS gemcitabine Model: Single Group
Technology
Brachytherapy Assignment|Masking:
Double Blind (Subject,
Investigator, Outcomes
Assessor)|Primary
Purpose: Treatment

National Health
Research Institutes,
Taiwan|National
Taiwan University
Hospital|Chang Gung
Memorial
Hospital|Taipei
Veterans General
Hospital,Taiwan|Mack Observational Model:
A Phase III Study of Enrolling by
8 NCT00994721 ay Memorial Phase III 265 Case Control|Time 26-Mar-08 Feb-09 Jan-15 11-Oct-09 Oct-09 Jan-12
Pancreatic Cancer invitation
Hospital|Taichung Perspective: Prospective
Veterans General
Hospital|National
Cheng-Kung
University
Hospital|Kaohsiung
Veterans General
Hospital.|Kaohsiung
Medical University

Gemcitabine With or
Drug: capecitabine|Drug: Allocation:
Without Capecitabine
dalteparin|Drug: gemcitabine Groupe Cooperateur Randomized|Control:
and/or Dalteparin in
42 NCT00662688 Recruiting hydrochloride|Genetic: mutation Multidisciplinaire en Phase III 136 Active Control|Primary 18-Apr-08 Oct-07 1-Dec-09 Jul-09 Jan-12
Treating Patients With
analysis|Other: laboratory Oncologie (GERCOR) Purpose: Supportive
Metastatic Pancreatic
biomarker analysis Care
Cancer

Control:
Uncontrolled|Endpoint
Safety and Classification:
Immunogenicity of Human Biological: Human Safety/Efficacy
283 NCT00677677 Papillomavirus (HPV) Recruiting papillomavirus quadrivalent University of Alberta Phase III 50 Study|Intervention 12-May-08 May-08 Sep-10 11-Feb-10 Feb-10 Sep-10
Vaccine in Solid Organ vaccine Model: Single Group
Transplant Recipients Assignment|Masking:
Open Label|Primary
Purpose: Prevention

11 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation:
Randomized|Endpoint
Classification: Efficacy
Procedure: Standard
Study|Intervention
Standardization of Surgery pancreatoduodenectomy|Proced Seoul National
75 NCT00679913 Recruiting Phase III 216 Model: Parallel 15-May-08 Nov-05 Nov-10 17-May-08 May-08 Nov-09
on the Pancreatic Cancer ure: Extended University Hospital
Assignment|Masking:
pancreatoduodenectomy
Single Blind
(Subject)|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Efficacy and Safety of Placebo Control|Endpoint
Masitinib 9 mg/kg/Day in Classification:
Combination With Safety/Efficacy
Gemcitabine Compared to Study|Intervention
Drug: masitinib (AB1010)|Drug:
35 NCT00789633 Placebo in Combination Recruiting AB Science Phase III 320 Model: Parallel 12-Nov-08 Nov-08 Nov-11 7-Aug-09 Aug-09 Nov-10
placebo
With Gemcitabine in Assignment|Masking:
Treatment of Patients With Double Blind (Subject,
Advanced/Metastatic Caregiver, Investigator,
Pancreatic Cancer Outcomes
Assessor)|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Active Control|Endpoint
Intraoperative Celiac
Classification: Efficacy
Plexus Neurolysis for
Thomas Jefferson Study|Intervention
77 NCT00806611 Patients With Operable Recruiting Procedure: Alcohol Block Phase III 290 10-Dec-08 Sep-08 Dec-11 17-Sep-09 Sep-09 Dec-10
University Model: Parallel
Pancreatic and
Assignment|Masking:
Periampullary Cancer
Double Blind (Subject,
Investigator)|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Uncontrolled|Interventio
Early Enteral Feeding After
Procedure: Enteral Feeding and n Model: Parallel
86 NCT00809081 Pylorus Preserving Recruiting Yonsei University Phase III 38 15-Dec-08 Jul-07 Jan-10 15-Dec-08 Dec-08 Jun-09
Total Parental Support Assignment|Masking:
Pancreatoduodenectomy
Double Blind (Subject,
Investigator)|Primary
Purpose: Treatment

12 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Istituti Tumori
Giovanni Paolo
II|Gruppo Oncologico
Italia Allocation:
Meridionale(GOIM)|G Randomized|Endpoint
Gemcitabine or
ruppo Italiano per lo Classification: Efficacy
Gemcitabine and Cisplatin
Active, not Drug: gemcitabine|Drug: studio dei Carcinomi Study|Intervention
78 NCT00813696 in the Treatment of Phase III 400 22-Dec-08 Apr-02 Sep-09 22-Dec-08 Dec-08 Mar-09
recruiting cisplatin dell'Apparato Model: Parallel
Advanced Pancreatic
Digerente|Gruppo Assignment|Masking:
Cancer
Oncologico Italiano di Open Label|Primary
Ricerca Purpose: Treatment
Clinica|Cattedra di
Endocrinochirurgia,
Università di Verona

University Hospital,
Gasthuisberg|Erasme
ULB,
Brussels|Jolimont,
Brussels|St.Lucas,
Reduced Pancreatic Fistula
Brugge|AZ.Groeninge
Rate Following
, Kortrijk|Universite
Pancreaticoduodenectomy: Procedure: Allocation:
Catholique Louvain
84 NCT00830778 Trial on Recruiting Pancreaticojejunostomy|Procedu Phase III 336 Randomized|Primary 27-Jan-09 Jun-09 Jun-12 13-Nov-09 Nov-09 Dec-11
(UCL),
Pancreaticogastrostomy re: Pancreaticogastrostomy Purpose: Treatment
Brussels|St.Joseph,
Versus
Liège|University
Pancreaticojejunostomy
Hospital,
Antwerp|Jan Palfijn,
Antwerp|St.Jan,
Brugge|Monica,
Deurne

Endpoint Classification:
Study of Lanreotide Safety
Autogel 120mg in Patients Study|Intervention
Enrolling by
93 NCT00842348 With Non-functioning Drug: lanreotide Ipsen Phase III 140 Model: Single Group 11-Feb-09 Sep-08 Dec-14 17-Feb-10 Feb-10 Dec-13
invitation
Entero- Pancreatic Assignment|Masking:
Endocrine Tumour Open Label|Primary
Purpose: Treatment

Allocation:
Randomized|Intervention
A Trial of Patients With Drug: ABI-
Abraxis BioScience Model: Parallel
36 NCT00844649 Metastatic Adenocarcinoma Recruiting 007/Gemcitabine|Drug: Phase III 630 13-Feb-09 Mar-09 Jun-12 13-Apr-10 Dec-09 Dec-10
Inc. Assignment|Masking:
of the Pancreas Gemcitabine
Open Label|Primary
Purpose: Treatment

Beth Israel Allocation:


Deaconess Medical Randomized|Endpoint
Enoxaparin
Center|Massachusett Classification: Efficacy
Thromboprophylaxis in
s General Study|Intervention
76 NCT00908960 Cancer Patients With Recruiting Drug: Enoxaparin Phase III 227 26-May-09 May-09 27-Jul-09 Jul-09 Apr-11
Hospital|North Shore Model: Parallel
Elevated Tissue Factor
Medical Assignment|Masking:
Bearing Microparticles
Center|Sanofi- Open Label|Primary
Aventis Purpose: Prevention
13 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation:
Randomized|Control:
Placebo Control|Endpoint
Prevention of Venous and
Classification: Efficacy
Arterial Thromboembolism,
Study|Intervention
in Cancer Patients
Drug: Nadroparin calcium|Drug: Italfarmaco|Carlo Model: Crossover
97 NCT00951574 Undergoing Completed Phase III 1166 31-Jul-09 Oct-03 Jul-08 3-Aug-09 Aug-09 May-07
saline solution (placebo) Bianchini Assignment|Masking:
Chemotherapy, With a Low
Double Blind (Subject,
Molecular Weight Heparin
Caregiver, Investigator,
(Nadroparin Calcium)
Outcomes
Assessor)|Primary
Purpose: Prevention

Allocation:
Randomized|Endpoint
Classification: Efficacy
Study|Intervention
Trial of Endoscopic Centre hospitalier de
Procedure: EUS-guided celiac Model: Parallel
62 NCT00974948 Ultrasound (EUS) - Guided Completed l'Université de Phase III 100 10-Sep-09 Apr-06 Dec-08 10-Sep-09 Sep-09 Dec-08
plexus neurolysis Assignment|Masking:
Celiac Plexus Neurolysis Montréal (CHUM)
Double Blind (Subject,
Caregiver, Outcomes
Assessor)|Primary
Purpose: Treatment

Allocation:
Randomized|Endpoint
Classification:
Safety/Efficacy
Placebo Controlled Trial of Memorial Sloan-
Study|Intervention
SOM230 for the Reduction Drug: Pasireotide Kettering Cancer
64 NCT00994110 Recruiting Phase III 300 Model: Parallel 13-Oct-09 Oct-09 Oct-11 6-Apr-10 Apr-10 Oct-11
of Post-Pancreatectomy (SOM230)|Other: placebo Center|Novartis
Assignment|Masking:
Fistula, Leak, and Abscess Pharmaceuticals
Double Blind (Subject,
Caregiver,
Investigator)|Primary
Purpose: Treatment

Gemcitabine Hydrochloride
Drug: capecitabine|Drug:
With or Without Erlotinib
erlotinib hydrochloride|Drug: Radiation Therapy
Hydrochloride Followed By Allocation:
fluorouracil|Drug: gemcitabine Oncology
Chemotherapy With or Randomized|Masking:
3 NCT01013649 Recruiting hydrochloride|Radiation: 3- Group|National Phase III 950 13-Nov-09 Nov-09 17-Apr-10 Apr-10 Apr-15
Without Radiation Therapy Open Label|Primary
dimensional conformal radiation Cancer Institute
in Treating Patients With Purpose: Treatment
therapy|Radiation: intensity- (NCI)
Pancreatic Cancer That Has
modulated radiation therapy
Been Removed By Surgery

14 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation:
Randomized|Control:
Active Control|Endpoint
Classification:
Vaccine Study for
Not yet Biological: HyperAcute- NewLink Genetics Safety/Efficacy
20 NCT01072981 Surgically Resected Phase III 722 18-Feb-10 Mar-10 Jan-14 26-Feb-10 Feb-10 Jan-14
recruiting Pancreatic Cancer Vaccine Corporation Study|Intervention
Pancreatic Cancer
Model: Parallel
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Klinikum der
Universitaet
Muenchen, Allocation:
Grosshadern|Europea Randomized|Control:
n Society for Active Control|Endpoint
Device: Gemcitabine + regional Hyperthermic Classification: Efficacy
Hyperthermia European Not yet
53 NCT01077427 hyperthermia|Drug: Oncology|Institute Phase III 366 Study|Intervention 25-Feb-10 Jan-11 Jan-16 15-Mar-10 Mar-10 Jan-16
Adjuvant Trial recruiting
Gemcitabine for Medical Model: Parallel
Informatics, Biometry Assignment|Masking:
and Epidemiology, Open Label|Primary
Munich|ClinAssess Purpose: Treatment
GmbH, Leverkusen,
Germany

European
Gemcitabine and Radiation Organization for
Therapy Compared With Drug: gemcitabine Research and Allocation:
Gemcitabine Alone in Active, not hydrochloride|Procedure: Treatment of Phase II|Phase Randomized|Control:
49 NCT00064207 538 8-Jul-03 May-03 21-Nov-09 Nov-06
Treating Patients Who recruiting adjuvant therapy|Radiation: Cancer|Federation III Active Control|Primary
Have Undergone Surgery radiation therapy Francophone de Purpose: Treatment
for Pancreatic Cancer Cancerologie
Digestive

Combination Drug: fluorouracil|Drug:


Allocation:
Chemotherapy as First- gemcitabine hydrochloride|Drug: Federation Nationale
Active, not Phase II|Phase Randomized|Control:
43 NCT00112658 Line Therapy in Treating irinotecan hydrochloride|Drug: des Centres de Lutte 348 2-Jun-05 Nov-04 20-Feb-10 Dec-06
recruiting III Active Control|Primary
Patients With Metastatic leucovorin calcium|Drug: Contre le Cancer
Purpose: Treatment
Pancreatic Cancer oxaliplatin

Allocation: Non-
Randomized|Control:
Orathecin + Gemcitabine Uncontrolled|Endpoint
Versus Placebo + Classification:
Gemcitabine in Phase II|Phase Safety/Efficacy
61 NCT00113256 Completed Drug: Rubitecan SuperGen 30 6-Jun-05 Feb-05 12-Oct-09 Oct-09
Chemonaive Non- III Study|Intervention
Resectable Pancreatic Model: Single Group
Cancer Assignment|Masking:
Open Label|Primary
Purpose: Treatment

15 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation: Non-
Randomized|Control:
Active Control|Endpoint
Irinotecan, Gemcitabine Classification: Efficacy
Active, not Rambam Health Care Phase II|Phase
68 NCT00192712 and Radiation Therapy for Drug: irinotecan, gemcitabine 20 Study|Intervention 11-Sep-05 Nov-02 Feb-05 13-Dec-05 Sep-05
recruiting Campus III
Pancreatic Cancer Model: Single Group
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Active Control|Endpoint
Massachusetts
Classification: Efficacy
EUS-Guided Pancreatic General
Procedure: Ethanol injection into Phase II|Phase Study|Intervention
82 NCT00233038 Injection of Cyst (EPIC) Completed Hospital|Indiana 50 3-Oct-05 Jan-05 Mar-08 25-Jun-08 Jun-08 Dec-07
a cyst III Model: Crossover
Trial University School of
Assignment|Masking:
Medicine
Double Blind (Subject,
Investigator)|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Placebo Control|Endpoint
Study to Evaluate the
Classification:
Clinical Benefit Response in
Auron Healthcare Phase II|Phase Safety/Efficacy
81 NCT00332280 Cancer Patients With Recruiting Drug: AMT2003 200 31-May-06 May-06 Dec-08 29-Nov-06 Nov-06
GmbH III Study|Intervention
Advanced Disease With
Model: Parallel
AMT2003 Versus Placebo
Assignment|Masking:
Single Blind|Primary
Purpose: Treatment

Allocation: Non-
Randomized|Control:
Safety/Efficacy of Uncontrolled|Endpoint
Everolimus in Adults With Classification:
Advanced Pancreatic Active, not Phase II|Phase Safety/Efficacy
79 NCT00363051 Drug: Everolimus Novartis 144 2-Aug-06 Jun-06 18-Nov-09 Nov-09
Neuroendocrine Cancer Not recruiting III Study|Intervention
Responsive to Model: Single Group
Chemotherapy Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Control:
Efficacy Study of Uncontrolled|Endpoint
Endoscopic Classification:
Ultrasonography (EUS)- Procedure: Endoscopic Safety/Efficacy
Phase II|Phase
55 NCT00689715 Guided Ethanol Lavage Recruiting ultrasonography-guided ethanol Asan Medical Center 50 Study|Intervention 2-Jun-08 Jun-06 3-Jun-08 Jun-08 May-09
III
With Paclitaxel Injection lavage with paclitaxel injection Model: Single Group
for Cystic Tumors of the Assignment|Masking:
Pancreas Open Label|Primary
Purpose: Treatment

16 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation:
Randomized|Control:
Endoscopic Stenting Active Control|Endpoint
Versus Surgical Bypass for Procedure: Surgical Classification: Efficacy
Not yet University of Phase II|Phase
66 NCT00753441 Low Bile Duct Obstruction bypass|Procedure: Endoscopic 100 Study|Intervention 15-Sep-08 Sep-08 Sep-10 15-Sep-08 Jul-08 Sep-10
recruiting Heidelberg III
by Cancer of the Pancreatic stenting Model: Parallel
Head Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Active Control|Endpoint
Drug: enoxaparin|Drug: CONKO-
Chemotherapy With or Classification: Efficacy
chemotherapy with LMWH - Studiengruppe|Sanofi- Phase II|Phase
65 NCT00785421 Without Enoxaparin in Completed 540 Study|Intervention 4-Nov-08 Apr-04 Jun-09 12-Jun-09 Jun-09 Jan-09
enoxaparin|Drug: only Aventis|Amgen|Eli III
Pancreatic Cancer Model: Parallel
chemotherapy Lilly and Company
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Gemcitabine Hydrochloride
With or Without
Drug: capecitabine|Drug:
Combination
cisplatin|Drug: epirubicin Allocation:
Chemotherapy and Istituto Scientifico H. Phase II|Phase
48 NCT00960284 Recruiting hydrochloride|Drug: 102 Randomized|Primary 14-Aug-09 Jun-03 29-Aug-09 Aug-09 Jun-09
Radiation Therapy in San Raffaele III
fluorouracil|Drug: gemcitabine Purpose: Treatment
Treating Patients With
hydrochloride
Stage IB, Stage II, or
Stage III Pancreatic Cancer

Biological: allogeneic tumor cell


vaccine|Biological: autologous
Cyclophosphamide Plus tumor cell vaccine|Biological:
Vaccine Therapy in recombinant interferon St. Vincent Medical Primary Purpose:
124 NCT00002475 Completed Phase II 40 1-Nov-99 Apr-91 11-Jun-09 Nov-08 Dec-07
Treating Patients With alfa|Biological: recombinant Center - Los Angeles Treatment
Advanced Cancer interferon gamma|Biological:
sargramostim|Drug:
cyclophosphamide

Drug: dexamethasone|Drug:
Radiation Therapy Plus
fluorouracil|Radiation:
Chemotherapy in Treating Center for Molecular Primary Purpose:
252 NCT00002689 Completed brachytherapy|Radiation: Phase II 48 1-Nov-99 Sep-95 6-Feb-09 Jun-07
Patients With Pancreatic Medicine Treatment
phosphorus P32|Radiation:
Cancer
radiation therapy

Combination Southwest Oncology


Drug: dipyridamole|Drug:
Chemotherapy in Treating Group|National Primary Purpose:
96 NCT00003018 Completed fluorouracil|Drug: leucovorin Phase II 55 1-Nov-99 Sep-97 23-Jul-08 May-07
Patients With Stage II or Cancer Institute Treatment
calcium|Drug: mitomycin C
Stage III Pancreatic Cancer (NCI)

Vaccine Therapy, Biological: ALVAC-CEA Lombardi Cancer


Interleukin-2, and vaccine|Biological: Research Allocation:
Active, not
127 NCT00003125 Sargramostim in Treating aldesleukin|Biological: Center|National Phase II 24 Randomized|Primary 1-Nov-99 Jan-98 6-Feb-09 May-07
recruiting
Patients With Advanced sargramostim|Biological: Cancer Institute Purpose: Treatment
Tumors vaccinia-CEA vaccine (NCI)
17 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Biological Therapy in
Treating Patients With Duke
Biological: carcinoembryonic
Stage I, Stage II, or Stage Active, not University|National Primary Purpose:
88 NCT00003434 antigen peptide 1|Biological: Phase II 24 1-Nov-99 Jun-98 6-Feb-09 Jun-01
III Pancreatic Cancer That recruiting Cancer Institute Treatment
hepatitis B antigen peptide
Has Been Surgically (NCI)
Removed

Gemcitabine Plus Radiation Cancer and Leukemia


Drug: gemcitabine
Therapy in Treating Active, not Group B|National Primary Purpose:
146 NCT00003546 hydrochloride|Radiation: Phase II 40 1-Nov-99 Sep-98 6-Feb-09 Aug-05
Patients With Pancreatic recruiting Cancer Institute Treatment
radiation therapy
Cancer (NCI)

Irofulvene in Treating
Active, not San Antonio Cancer Primary Purpose:
94 NCT00003760 Patients With Stage III or Drug: irofulven Phase II 50 1-Nov-99 Oct-98 23-Jul-08 Jul-00
recruiting Institute Treatment
Stage IV Pancreatic Cancer

Radiation Therapy Plus


Radiation Therapy
Paclitaxel in Treating
Oncology
Patients With Drug: paclitaxel|Radiation: Primary Purpose:
141 NCT00003591 Completed Group|National Phase II 100 1-Nov-99 Nov-98 6-Feb-09 Mar-08 Feb-04
Nonmetastatic, radiation therapy Treatment
Cancer Institute
Unresectable Pancreatic
(NCI)
Cancer

Chemotherapy Compared
Biological: tumor infiltrating Allocation:
to Biological Therapy in Active, not Meyer
221 NCT00003780 lymphocyte therapy|Drug: Phase II 150 Randomized|Primary 1-Nov-99 Dec-98 6-Feb-09 May-07
Treating Patients With recruiting Pharmaceuticals
gemcitabine hydrochloride Purpose: Treatment
Cancer of the Pancreas

Indiana University
Perillyl Alcohol Followed by
School of
Surgery in Treating Drug: perillyl alcohol|Procedure: Primary Purpose:
91 NCT00003769 Completed Medicine|National Phase II 1-Nov-99 Feb-99 17-Sep-09 Sep-09
Patients With Stage II or surgical procedure Treatment
Cancer Institute
Stage III Pancreatic Cancer
(NCI)

Biological: anti-thymocyte
Peripheral Stem Cell
globulin|Biological: therapeutic
Transplant and White
allogeneic lymphocytes|Drug: National Heart, Lung,
Blood Cell Transfusions in Active, not Primary Purpose:
144 NCT00003839 cyclophosphamide|Drug: and Blood Institute Phase II 150 1-Nov-99 Mar-99 6-Feb-09 Nov-08 Dec-09
Treating Patients With recruiting Treatment
cyclosporine|Drug: fludarabine (NHLBI)
Refractory Metastatic Solid
phosphate|Procedure: peripheral
Tumors
blood stem cell transplantation

Memorial Sloan-
Photodynamic Therapy in
Kettering Cancer
Treating Patients With Primary Purpose:
238 NCT00003923 Completed Drug: porfimer sodium Center|National Phase II 30 1-Nov-99 Mar-99 3-Dec-09 Dec-09 Feb-02
Cancer of the Bile Duct, Treatment
Cancer Institute
Gallbladder, or Pancreas
(NCI)

Combination
Barbara Ann
Chemotherapy in Treating
Drug: cisplatin|Drug: Karmanos Cancer
Patients With Stage III or Primary Purpose:
98 NCT00004003 Completed fluorouracil|Drug: gemcitabine Institute|National Phase II 30 1-Nov-99 Apr-99 13-Apr-10 Apr-10 Aug-03
Stage IV Pancreatic Cancer Treatment
hydrochloride Cancer Institute
That Cannot Be Removed
(NCI)
by Surgery

18 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Combination Eastern Cooperative


Chemotherapy in Treating Oncology
Drug: docetaxel|Drug: Primary Purpose:
173 NCT00003810 Patients With Locally Completed Group|National Phase II 1-Nov-99 Apr-99 23-Jul-08 Aug-04
gemcitabine hydrochloride Treatment
Advanced or Metastatic Cancer Institute
Cancer of the Pancreas (NCI)

Vaccine Therapy, Biological: allogeneic tumor cell


Chemotherapy, and GM- vaccine|Biological: recombinant
St. Vincent Medical Primary Purpose:
181 NCT00002773 CSF in Treating Patients Completed interferon alfa|Biological: Phase II 1-Nov-99 Dec-08 6-Feb-09 Apr-07
Center - Los Angeles Treatment
With Advanced Pancreatic sargramostim|Drug:
Cancer cyclophosphamide

Drug: antineoplaston A10|Drug:


antineoplaston AS2-
Antineoplaston Therapy in 1|Procedure: alternative product
Treating Patients With therapy|Procedure: biological
Neuroendocrine Tumor therapy|Procedure: biologically
Burzynski Research Primary Purpose:
296 NCT00003514 That Is Metastatic or Withdrawn based therapies|Procedure: Phase II 1-Nov-99 4-Dec-06 Dec-06
Institute Treatment
Unlikely to Respond to cancer prevention
Surgery or Radiation intervention|Procedure:
Therapy complementary and alternative
therapy|Procedure:
differentiation therapy

Interferon and Octreotide National Institute of


to Treat Zollinger-Ellison Diabetes and Primary Purpose:
303 NCT00001228 Completed Drug: Interferon Phase II 50 3-Nov-99 Oct-88 Sep-07 7-Sep-07 Sep-07
Syndrome and Advanced Digestive and Kidney Treatment
Non-B Islet Cell Cancer Diseases (NIDDK)

Gemcitabine Plus
North Central Cancer
Oxaliplatin in Treating
Treatment
Patients With Refractory Drug: gemcitabine Primary Purpose:
147 NCT00004190 Completed Group|National Phase II 21-Jan-00 Oct-99 23-Jul-08 Apr-07
Locally Advanced or hydrochloride|Drug: oxaliplatin Treatment
Cancer Institute
Metastatic Pancreatic
(NCI)
Cancer

Docetaxel and Gemcitabine


Compared With Docetaxel European
Drug: cisplatin|Drug: Allocation:
and Cisplatin in Treating Active, not Organization for
205 NCT00004884 docetaxel|Drug: gemcitabine Phase II Randomized|Primary 7-Mar-00 Jul-99 23-Jul-08 Jun-07
Patients With Metastatic or recruiting Research and
hydrochloride Purpose: Treatment
Locally Advanced Treatment of Cancer
Pancreatic Cancer

Octreotide as Palliative Robert H. Lurie


Therapy for Cancer- Cancer
Primary Purpose:
114 NCT00004895 Related Bowel Obstruction Completed Drug: octreotide acetate Center|National Phase II 7-Mar-00 Oct-99 9-May-09 Nov-02
Supportive Care
That Cannot Be Removed Cancer Institute
by Surgery (NCI)

Gemcitabine With or
Allocation:
Without CI-994 in Treating Active, not Drug: gemcitabine Pfizer Incorporated -
231 NCT00004861 Phase II Randomized|Primary 7-Mar-00 Oct-99 9-May-09 Jun-07
Patients With Advanced recruiting hydrochloride|Drug: tacedinaline Ann Arbor
Purpose: Treatment
Pancreatic Cancer

19 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Glufosfamide With or
European
Without Hydration in Allocation:
Active, not Organization for
204 NCT00005053 Treating Patients With Drug: glufosfamide Phase II Randomized|Primary 6-Apr-00 Dec-99 23-Jul-08 Jun-07
recruiting Research and
Advanced Pancreatic Purpose: Treatment
Treatment of Cancer
Cancer

Control:
Uncontrolled|Endpoint
University of
Classification:
Alabama at
ISIS 2503 in Treating Safety/Efficacy
Birmingham|National
131 NCT00005594 Patients With Advanced Completed Drug: ISIS 2503 Phase II 4 Study|Intervention 2-May-00 Jul-00 1-Dec-09 Dec-09 Dec-00
Cancer Institute
Cancer of the Pancreas Model: Single Group
(NCI)|Isis
Assignment|Masking:
Pharmaceuticals
Open Label|Primary
Purpose: Treatment

Cetuximab Plus
University of
Gemcitabine in Treating
Alabama at
Patients With Locally Biological: cetuximab|Drug: Primary Purpose:
166 NCT00005591 Completed Birmingham|National Phase II 2-May-00 30-May-09 Apr-07
Advanced, Metastatic, or gemcitabine hydrochloride Treatment
Cancer Institute
Recurrent Cancer of the
(NCI)
Pancreas

R115777 in Treating Southwest Oncology


Patients With Locally Active, not Group|National Primary Purpose:
139 NCT00005832 Drug: tipifarnib Phase II 2-Jun-00 Jun-00 23-Jul-08 Apr-07
Advanced or Metastatic recruiting Cancer Institute Treatment
Pancreatic Cancer (NCI)

Gemcitabine and
Oxaliplatin in Treating Groupe Cooperateur
Active, not Drug: gemcitabine Primary Purpose:
158 NCT00006117 Patients With Locally Multidisciplinaire en Phase II 3-Aug-00 Sep-99 29-Oct-09 Oct-09
recruiting hydrochloride|Drug: oxaliplatin Treatment
Advanced or Metastatic Oncologie (GERCOR)
Pancreatic Cancer

Gemcitabine and ISIS North Central Cancer


2503 in Treating Patients Treatment
Drug: ISIS 2503|Drug: Primary Purpose:
159 NCT00006467 With Advanced or Completed Group|National Phase II 6-Nov-00 Feb-01 23-Jul-08 Apr-07
gemcitabine hydrochloride Treatment
Metastatic Cancer of the Cancer Institute
Pancreas (NCI)

Chemotherapy in Treating Drug: fluorouracil|Drug:


Patients With Locally gemcitabine hydrochloride|Drug: Groupe Cooperateur
Active, not Primary Purpose:
211 NCT00010088 Advanced or Metastatic leucovorin calcium|Procedure: Multidisciplinaire en Phase II 2-Feb-01 Jan-99 6-Feb-09 Apr-07
recruiting Treatment
Cancer of the Pancreas or conventional surgery|Radiation: Oncologie (GERCOR)
Bile Duct radiation therapy

Fluorouracil Plus Radiation


Groupe Cooperateur
Therapy Following Surgery Active, not Drug: fluorouracil|Radiation: Primary Purpose:
189 NCT00010062 Multidisciplinaire en Phase II 2-Feb-01 Oct-00 6-Feb-09 Apr-07
in Treating Patients With recruiting radiation therapy Treatment
Oncologie (GERCOR)
Pancreatic Cancer

Biological: carcinoembryonic
Vaccine Therapy in University of Allocation:
antigen peptide 1-6D|Biological:
Treating Patients With Texas|National Randomized|Control:
128 NCT00012246 Completed incomplete Freund's Phase II 3-Mar-01 Jul-02 6-Feb-09 Jan-06
Cancer of the Cancer Institute Active Control|Primary
adjuvant|Biological:
Gastrointestinal Tract (NCI) Purpose: Treatment
sargramostim

20 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Southwest Oncology
BMS-247550 in Treating
Group|National Primary Purpose:
140 NCT00016965 Patients With Advanced Completed Drug: ixabepilone Phase II 6-Jun-01 Jul-01 23-Jul-08 Apr-03
Cancer Institute Treatment
Pancreatic Cancer
(NCI)

Biological:
aldesleukin|Biological: mutant
p53 peptide pulsed dendritic cell
Vaccine Therapy and vaccine|Biological: ras peptide
Biological Therapy in cancer vaccine|Biological: National Cancer Primary Purpose:
259 NCT00019084 Completed Phase II 11-Jul-01 Feb-96 6-Feb-09 Apr-07
Treating Patients With sargramostim|Biological: Institute (NCI) Treatment
Advanced Cancer therapeutic autologous
lymphocytes|Biological:
therapeutic tumor infiltrating
lymphocytes

Biological:
Vaccine Therapy Plus
aldesleukin|Biological: ras
Biological Therapy in National Cancer Primary Purpose:
169 NCT00019331 Completed peptide cancer Phase II 11-Jul-01 Oct-97 6-Feb-09 Apr-04
Treating Adults With Institute (NCI) Treatment
vaccine|Biological:
Metastatic Solid Tumors
sargramostim|Drug: DetoxPC

Combination
Albert Einstein
Chemotherapy Plus
Biological: filgrastim|Biological: College of Medicine
Interferon Alfa Followed by
Active, not recombinant interferon of Yeshiva Primary Purpose:
122 NCT00019474 Filgrastim in Treating Phase II 60 11-Jul-01 Mar-98 6-Feb-09 Apr-07
recruiting alfa|Drug: fluorouracil|Drug: University|National Treatment
Patients With
hydroxyurea Cancer Institute
Gastrointestinal Tract
(NCI)
Cancer

Isolated Hepatic Perfusion


With Melphalan in Treating Drug: isolated perfusion|Drug: Masking: Open
Active, not National Cancer
294 NCT00019786 Patients With Primary melphalan|Procedure: Phase II 67 Label|Primary Purpose: 11-Jul-01 Aug-99 6-Feb-09 Jan-06
recruiting Institute (NCI)
Unresectable Liver Cancer conventional surgery Treatment
or Liver Metastases

BBR 3464 in Treating


Patients With Locally
Advanced or Metastatic Active, not Primary Purpose:
155 NCT00024362 Drug: BBR 3464 Theradex Phase II 13-Sep-01 May-01 23-Jul-08 Apr-07
Pancreatic Cancer That recruiting Treatment
Cannot be Treated With
Surgery

Combination
Wake Forest
Chemotherapy Plus
Drug: gemcitabine University Baptist
Radiation Therapy in
hydrochloride|Drug: irinotecan Medical Primary Purpose:
164 NCT00025168 Treating Patients With Completed Phase II 11-Oct-01 Nov-01 20-Aug-09 Aug-09
hydrochloride|Radiation: Center|National Treatment
Locally Advanced
radiation therapy Cancer Institute
Unresectable Pancreatic
(NCI)
Cancer

Combination
Drug: fluorouracil|Drug: Cancer and Leukemia
Chemotherapy and
gemcitabine Group B|National Primary Purpose:
154 NCT00026130 Radiation Therapy in Completed Phase II 9-Nov-01 Sep-01 9-Mar-10 Jul-04 Mar-10
hydrochloride|Radiation: Cancer Institute Treatment
Treating Patients With
radiation therapy (NCI)
Pancreatic Cancer

21 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Combination
North Central Cancer
Chemotherapy Plus Drug: cisplatin|Drug:
Treatment
Radiation Therapy in gemcitabine Primary Purpose:
161 NCT00026403 Completed Group|National Phase II 9-Nov-01 Sep-01 4-Aug-09 Jul-09 Jul-09
Treating Patients With hydrochloride|Radiation: Treatment
Cancer Institute
Advanced Pancreatic radiation therapy
(NCI)
Cancer

Combination
Chemotherapy Plus Drug: gemcitabine Radiation Therapy
Radiation Therapy With or hydrochloride|Drug: Oncology
Primary Purpose:
187 NCT00026104 Without Tipifarnib in Completed paclitaxel|Drug: Group|National Phase II 9-Nov-01 Nov-01 6-Apr-10 Sep-03 Mar-10
Treatment
Treating Patients With tipifarnib|Radiation: radiation Cancer Institute
Locally Advanced therapy (NCI)
Pancreatic Cancer

Bevacizumab and University of


Masking: Open
Gemcitabine in Treating Biological: bevacizumab|Drug: Chicago|National
182 NCT00028834 Completed Phase II Label|Primary Purpose: 4-Jan-02 Feb-02 6-Feb-09 Oct-04
Patients With Advanced gemcitabine hydrochloride Cancer Institute
Treatment
Pancreatic Cancer (NCI)

Albert Einstein
Paclitaxel and Bryostatin-1
College of Medicine
in Treating Patients With Masking: Open
Active, not Drug: bryostatin 1|Drug: of Yeshiva
152 NCT00031694 Locally Advanced Phase II Label|Primary Purpose: 8-Mar-02 Jan-02 23-Jul-08 Apr-04
recruiting paclitaxel University|National
Unresectable or Metastatic Treatment
Cancer Institute
Pancreatic Cancer
(NCI)

CI-1040 in Treating University of


Patients With Advanced Alabama at
Primary Purpose:
123 NCT00033384 Breast, Colon, Pancreatic, Completed Drug: CI-1040 Birmingham|National Phase II 9-Apr-02 Feb-02 30-May-09 Dec-02
Treatment
or Non-Small Cell Lung Cancer Institute
Cancer (NCI)

Acupuncture and
Memorial Sloan-
Acupressure in Treating Procedure: complementary or
Kettering Cancer
Patients With Moderate or alternative medicine Primary Purpose:
90 NCT00040833 Completed Center|National Phase II 8-Jul-02 Feb-02 6-Feb-09 Jul-03
Severe Pain Related to procedure|Procedure: pain Supportive Care
Cancer Institute
Stage III or Stage IV therapy
(NCI)
Pancreatic Cancer

Biological: epoetin
alfa|Biological: filgrastim|Drug:
Chemotherapy and cisplatin|Drug: Eastern Cooperative
Allocation:
Radiation Therapy in fluorouracil|Drug: gemcitabine Oncology
Randomized|Control:
215 NCT00049348 Treating Patients With Completed hydrochloride|Procedure: Group|National Phase II 12-Nov-02 May-03 29-May-09 Jun-05 May-09
Active Control|Primary
Locally Advanced adjuvant therapy|Procedure: Cancer Institute
Purpose: Treatment
Pancreatic Cancer conventional surgery|Procedure: (NCI)
neoadjuvant therapy|Radiation:
radiation therapy

Arsenic Trioxide in Treating University of


Masking: Open
Patients With Pancreatic Chicago|National
165 NCT00053222 Completed Drug: arsenic trioxide Phase II Label|Primary Purpose: 27-Jan-03 Feb-03 23-Jul-08 Feb-04
Cancer That Has Not Cancer Institute
Treatment
Responded to Gemcitabine (NCI)

22 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Princess Margaret
Perifosine in Treating Hospital, Masking: Open
151 NCT00053924 Patients With Advanced Completed Drug: perifosine Canada|National Phase II Label|Primary Purpose: 5-Feb-03 May-03 23-Jul-08 Jul-04
Pancreatic Cancer Cancer Institute Treatment
(NCI)

Biological: recombinant
Adjuvant
interferon alfa|Drug: American College of
Chemoradiotherapy and Masking: Open
Active, not cisplatin|Drug: Surgeons|National
107 NCT00059826 Interferon Alfa in Treating Phase II Label|Primary Purpose: 6-May-03 Mar-03 6-Feb-09 Jan-06
recruiting fluorouracil|Procedure: adjuvant Cancer Institute
Patients With Resected Treatment
therapy|Radiation: radiation (NCI)
Pancreatic Cancer
therapy

Perifosine in Treating Eastern Cooperative


Patients With Locally Oncology Masking: Open
145 NCT00059982 Advanced, Unresectable, or Completed Drug: perifosine Group|National Phase II Label|Primary Purpose: 6-May-03 Jul-03 23-Jul-08 Aug-04
Metastatic Pancreatic Cancer Institute Treatment
Cancer (NCI)

Memorial Sloan-
Kettering Cancer Masking: Open
Alanosine in Treating
226 NCT00062283 Completed Drug: L-alanosine Center|National Phase II Label|Primary Purpose: 5-Jun-03 Mar-03 11-Dec-09 Dec-09 Dec-05
Patients With Cancer
Cancer Institute Treatment
(NCI)

3-AP and Gemcitabine in


Masking: Open
Treating Patients With Drug: gemcitabine
198 NCT00064051 Completed Vion Pharmaceuticals Phase II Label|Primary Purpose: 8-Jul-03 Jan-03 23-Aug-08 Aug-08 Aug-06
Unresectable or Metastatic hydrochloride|Drug: triapine
Treatment
Pancreatic Cancer

Chemotherapy, Interferon Biological: recombinant


M.D. Anderson
Alfa, and Radiation interferon alfa|Drug:
Cancer Masking: Open
Therapy in Treating cisplatin|Drug:
108 NCT00068575 Recruiting Center|National Phase II 44 Label|Primary Purpose: 10-Sep-03 May-03 6-Feb-09 Jul-07
Patients Who Have fluorouracil|Procedure: adjuvant
Cancer Institute Treatment
Undergone Surgery For therapy|Radiation: radiation
(NCI)
Pancreatic Cancer therapy

M.D. Anderson
CCI-779 in Treating
Cancer Masking: Open
Patients With Locally
196 NCT00075647 Completed Drug: temsirolimus Center|National Phase II Label|Primary Purpose: 9-Jan-04 Dec-03 23-Jul-08 Feb-05
Advanced or Metastatic
Cancer Institute Treatment
Pancreatic Cancer
(NCI)

3-AP and Gemcitabine in Princess Margaret


Treating Patients With Hospital, Masking: Open
Active, not Drug: gemcitabine
237 NCT00078975 Recurrent, Unresectable, Canada|National Phase II Label|Primary Purpose: 8-Mar-04 Apr-04 23-Jul-08 Nov-05
recruiting hydrochloride|Drug: triapine
or Metastatic Pancreatic Cancer Institute Treatment
Cancer (NCI)

Cisplatin, Metronomic Low-


Dose Interferon Alfa,
Biological: recombinant
Gemcitabine, and Fever-
interferon alfa|Drug: The University of Masking: Open
Range Whole-Body
227 NCT00082862 Recruiting cisplatin|Drug: gemcitabine Texas Health Science Phase II 48 Label|Primary Purpose: 14-May-04 Jul-02 14-Apr-09 Dec-08 Nov-12
Hyperthermia in Treating
hydrochloride|Procedure: Center, Houston Treatment
Patients With Inoperable or
hyperthermia treatment
Metastatic Pancreatic
Cancer

23 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

3-AP as First-Line or
Second-Line Therapy in
Mayo Clinic|National Masking: Open
Treating Patients With Active, not
190 NCT00085371 Drug: triapine Cancer Institute Phase II Label|Primary Purpose: 10-Jun-04 Jul-04 4-Sep-09 Dec-05
Locally Advanced or recruiting
(NCI) Treatment
Metastatic Adenocarcinoma
(Cancer) of the Pancreas

Drug: fluorouracil|Drug:
Combination gemcitabine hydrochloride|Drug:
Chemotherapy, and leucovorin calcium|Drug: University of
Masking: Open
Radiation Therapy in Active, not oxaliplatin|Procedure: adjuvant Nebraska|National
202 NCT00089024 Phase II 50 Label|Primary Purpose: 4-Aug-04 Feb-04 10-Mar-09 Mar-09 Dec-13
Treating Patients With recruiting therapy|Procedure: conventional Cancer Institute
Treatment
Locally Advanced surgery|Procedure: neoadjuvant (NCI)
Pancreatic Cancer therapy|Radiation: radiation
therapy

Bevacizumab and
Biological:
Gemcitabine Combined University of Allocation:
bevacizumab|Biological:
With Either Cetuximab or Active, not Chicago|National Randomized|Control:
240 NCT00091026 cetuximab|Drug: erlotinib Phase II 126 7-Sep-04 Sep-04 14-Apr-09 Dec-08
Erlotinib in Treating recruiting Cancer Institute Active Control|Primary
hydrochloride|Drug: gemcitabine
Patients With Advanced (NCI) Purpose: Treatment
hydrochloride
Pancreatic Cancer

Endpoint Classification:
Safety/Efficacy
Trial of Curcumin in Study|Intervention
M.D. Anderson
214 NCT00094445 Advanced Pancreatic Recruiting Drug: Curcumin Phase II 50 Model: Single Group 18-Oct-04 Nov-04 19-Feb-10 Feb-10 Nov-10
Cancer Center
Cancer Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Sorafenib and Gemcitabine


University of
in Treating Patients With Drug: gemcitabine Masking: Open
Active, not Chicago|National
234 NCT00095966 Locally Advanced or hydrochloride|Drug: sorafenib Phase II Label|Primary Purpose: 9-Nov-04 Sep-04 23-Jul-08 Jun-07 Sep-05
recruiting Cancer Institute
Metastatic Pancreatic tosylate Treatment
(NCI)
Cancer

Radiotherapy Combined
With Oxaliplatin and North Central Cancer
Drug: fluorouracil|Drug:
Fluorouracil Followed By Treatment Masking: Open
gemcitabine hydrochloride|Drug:
208 NCT00096070 Gemcitabine in Treating Completed Group|National Phase II 50 Label|Primary Purpose: 9-Nov-04 Dec-04 10-Mar-09 Mar-09 Mar-09
oxaliplatin|Radiation: radiation
Patients With Locally Cancer Institute Treatment
therapy
Advanced, Unresectable (NCI)
Pancreatic Cancer

Opioid Growth Factor in


Treating Patients With Masking: Open
Milton S. Hershey
262 NCT00109941 Advanced Pancreatic Completed Biological: opioid growth factor Phase II 50 Label|Primary Purpose: 3-May-05 Oct-03 6-Feb-09 Oct-07
Medical Center
Cancer That Cannot Be Treatment
Removed By Surgery

Paclitaxel in Treating
Patients With Unresectable Masking: Open
Drug: paclitaxel-loaded
179 NCT00111904 Locally Advanced or Completed Theradex Phase II 43 Label|Primary Purpose: 26-May-05 May-05 15-Dec-09 Jun-09 Aug-07
polymeric micelle
Metastatic Pancreatic 24 of 47 Treatment 4/20/2010, 8:16 PM
Cancer
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Capecitabine,
Bevacizumab, and
Radiation Therapy Followed Radiation Therapy
Biological: bevacizumab|Drug:
By Gemcitabine and Oncology Masking: Open
Active, not capecitabine|Drug: gemcitabine
210 NCT00114179 Bevacizumab in Treating Group|National Phase II Label|Primary Purpose: 13-Jun-05 Jan-05 1-Aug-09 Feb-06
recruiting hydrochloride|Radiation:
Patients With Locally Cancer Institute Treatment
radiation therapy
Advanced Pancreatic (NCI)
Cancer That Cannot Be
Removed By Surgery

Irradiated Donor
Lymphocyte Infusion in Cancer Institute of Control: Active
Biological: therapeutic allogeneic
Treating Patients With New Jersey|National Control|Masking: Open
246 NCT00161187 Recruiting lymphocytes|Other: laboratory Phase II 40 8-Sep-05 Dec-00 22-May-09 May-09
Relapsed or Refractory Cancer Institute Label|Primary Purpose:
biomarker analysis
Hematologic Cancer or (NCI) Treatment
Solid Tumor

Gemcitabine and Imatinib University of


Allocation: Non-
Mesylate as First-Line Medicine and
Drug: gemcitabine Randomized|Control:
Therapy in Treating Dentistry New
235 NCT00161213 Completed hydrochloride|Drug: imatinib Phase II 42 Uncontrolled|Masking: 8-Sep-05 Sep-05 Jul-09 12-Nov-09 Nov-09 Jul-09
Patients With Locally Jersey|National
mesylate Open Label|Primary
Advanced or Metastatic Cancer Institute
Purpose: Treatment
Pancreatic Cancer (NCI)

Allocation: Non-
Randomized|Control:
Dose
Comparison|Endpoint
Cetuximab, Radiotherapy
Drug: Classification:
and Twice Weekly Active, not Dartmouth-Hitchcock
248 NCT00225784 Erbitux/Gemcitabine|Procedure: Phase II 48 Safety/Efficacy 22-Sep-05 Feb-05 19-Jan-09 Jan-09 Aug-08
Gemcitabine to Treat recruiting Medical Center
Radiotherapy Study|Intervention
Pancreatic Cancer
Model: Single Group
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Endpoint Classification:
Calcitriol and Docetaxel in Efficacy
Oregon Health and
Treating Patients With Study|Intervention
Dietary Supplement: Science
201 NCT00238199 Metastatic or Locally Completed Phase II 25 Model: Single Group 12-Oct-05 Jun-02 Aug-06 6-Aug-09 Aug-09 Aug-06
calcitriol|Drug: docetaxel University|Sanofi-
Advanced Pancreatic Assignment|Masking:
Aventis
Cancer Open Label|Primary
Purpose: Treatment

25 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Drug: bevacizumab|Drug:
gemcitabine
hydrochloride|Procedure:
adjuvant therapy|Procedure:
anti-cytokine therapy|Procedure:
Gemcitabine Hydrochloride
antiangiogenesis
With or Without
therapy|Procedure: antibody
Bevacizumab in Treating National Cancer Primary Purpose:
133 NCT00253526 Withdrawn therapy|Procedure: biological Phase II 11-Nov-05 4-Dec-06 Dec-06
Patients Who Are Institute (NCI) Treatment
therapy|Procedure:
Undergoing Surgery for
chemotherapy|Procedure:
Pancreatic Cancer
conventional surgery|Procedure:
growth factor antagonist
therapy|Procedure: monoclonal
antibody therapy|Procedure:
surgery

Combination Biological: recombinant


Chemotherapy, Radiation interferon alfa|Drug:
Masonic Cancer
Therapy, and Interferon cisplatin|Drug:
Center, University of
Alfa in Treating Patients fluorouracil|Procedure: adjuvant Primary Purpose:
191 NCT00262951 Recruiting Minnesota|National Phase II 43 6-Dec-05 Jan-05 6-Feb-09 Oct-08 Jan-10
With Locally Advanced therapy|Procedure: conventional Treatment
Cancer Institute
Pancreatic Cancer That surgery|Procedure: neoadjuvant
(NCI)
Cannot Be Removed By therapy|Radiation: radiation
Surgery therapy

Gemcitabine and
Oxaliplatin Followed By
Radiation Therapy,
Drug: fluorouracil|Drug:
Fluorouracil, and Groupe Cooperateur Masking: Open
Active, not gemcitabine hydrochloride|Drug:
264 NCT00275119 Oxaliplatin in Treating Multidisciplinaire en Phase II Label|Primary Purpose: 10-Jan-06 Nov-03 6-Feb-09 Jan-06
recruiting oxaliplatin|Radiation: radiation
Patients With Locally Oncologie (GERCOR) Treatment
therapy
Advanced Pancreatic
Cancer That Cannot Be
Removed By Surgery

Biological: cetuximab|Drug:
bortezomib|Drug:
capecitabine|Drug:
Individualized Drug Sidney Kimmel
docetaxel|Drug: erlotinib
Treatment Selection Comprehensive
hydrochloride|Drug: gemcitabine Masking: Open
Process for Treating Cancer
225 NCT00276744 Suspended hydrochloride|Drug: irinotecan Phase II 40 Label|Primary Purpose: 12-Jan-06 Oct-05 6-Nov-09 Jul-09 Apr-11
Patients With Pancreatic Center|National
hydrochloride|Drug: mitomycin Treatment
Cancer That Can Be Cancer Institute
C|Drug: sirolimus|Drug:
Removed By Surgery (NCI)
thalidomide|Other: antitumor
drug screening assay|Procedure:
conventional surgery

26 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Biological: cetuximab|Biological:
Vaccine Therapy, Sidney Kimmel
sargramostim plasmid DNA
Cyclophosphamide, and Comprehensive
pancreatic tumor cell Masking: Open
Cetuximab in Treating Active, not Cancer
249 NCT00305760 vaccine|Drug: Phase II 60 Label|Primary Purpose: 21-Mar-06 Dec-05 26-Feb-09 Feb-09 Dec-08
Patients With Metastatic or recruiting Center|National
cyclophosphamide|Other: Treatment
Locally Advanced Cancer Institute
laboratory biomarker
Pancreatic Cancer (NCI)
analysis|Procedure: biopsy

Allocation: Non-
Drug: paclitaxel|Drug:
Randomized|Control:
oxaliplatin|Drug:
Historical
leucovorin|Drug: 5-
Weekly Dosing of an Control|Endpoint
fluorouracil|Drug:
Integrative Chemotherapy Seattle Cancer Classification:
glutathione|Drug: calcium and
103 NCT00323583 Combination to Treat Recruiting Treatment and Phase II 80 Safety/Efficacy 5-May-06 May-06 7-May-07 May-07
magnesium|Procedure:
Advanced Pancreatic Wellness Center Study|Intervention
Chemotherapy|Procedure:
Cancer Model: Single Group
Chemoprotection|Procedure:
Assignment|Masking:
Complementary and alternative
Open Label|Primary
therapy
Purpose: Treatment

Allocation: Non-
Beth Israel Randomized|Endpoint
Deaconess Medical Classification:
Center|National Safety/Efficacy
TMS for the Treatment of Active, not Procedure: Transcranial
256 NCT00324428 Institute of Diabetes Phase II 32 Study|Intervention 10-May-06 May-06 Feb-08 3-Feb-10 Feb-10 Feb-08
Pancreatic Cancer Pain recruiting Magnetic Stimulation
and Digestive and Model: Crossover
Kidney Diseases Assignment|Masking:
(NIDDK) Open Label|Primary
Purpose: Treatment

Gemcitabine, Cisplatin, and Drug: cisplatin|Drug:


Interdisziplinare
Radiation Therapy Followed gemcitabine Allocation:
Arbeitsgruppe
By Surgery or Surgery hydrochloride|Procedure: Randomized|Control:
Gastrointestinaler
253 NCT00335543 Alone in Treating Patients Recruiting adjuvant therapy|Procedure: Phase II 254 Active Control|Masking: 8-Jun-06 Jun-03 4-Aug-09 Aug-09 Jun-09
Tumore der
With Localized Pancreatic conventional surgery|Procedure: Open Label|Primary
Deutschen
Cancer That Can Be neoadjuvant therapy|Radiation: Purpose: Treatment
Krebsgesellschaft
Removed By Surgery radiation therapy

Genistein, Gemcitabine, Barbara Ann


Dietary Supplement:
and Erlotinib in Treating Karmanos Cancer Masking: Open
genistein|Drug: erlotinib
220 NCT00376948 Patients With Locally Completed Institute|National Phase II 40 Label|Primary Purpose: 13-Sep-06 May-05 13-Apr-10 Apr-10 Mar-10
hydrochloride|Drug: gemcitabine
Advanced or Metastatic Cancer Institute Treatment
hydrochloride
Pancreatic Cancer (NCI)

E7389 as Second-Line
Princess Margaret
Therapy in Treating
Hospital, Masking: Open
Patients With Locally
199 NCT00383760 Completed Drug: eribulin mesylate Canada|National Phase II 37 Label|Primary Purpose: 29-Sep-06 Apr-06 7-Oct-09 Jul-09 Feb-09
Advanced, Unresectable, or
Cancer Institute Treatment
Metastatic Pancreatic
(NCI)
Cancer

Vaccine Therapy in
Biological: sargramostim plasmid Sidney Kimmel Masking: Open
Treating Patients With Active, not
192 NCT00389610 DNA pancreatic tumor cell Comprehensive Phase II 100 Label|Primary Purpose: 18-Oct-06 Sep-06 20-Jul-09 Mar-09 Dec-09
Pancreatic Cancer That Has recruiting
vaccine Cancer Center Treatment
Been Removed by Surgery
27 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Cetuximab, Gemcitabine,
and Oxaliplatin Followed
Biological: cetuximab|Drug:
By Surgery or External-
capecitabine|Drug: gemcitabine
Beam Radiation Therapy
hydrochloride|Drug: Masking: Open
and Capecitabine in Active, not Medical University of
244 NCT00408564 oxaliplatin|Procedure: Phase II 42 Label|Primary Purpose: 6-Dec-06 Jan-06 6-Feb-09 Nov-08 Jan-11
Treating Patients With recruiting South Carolina
conventional surgery|Procedure: Treatment
Locally Advanced,
neoadjuvant therapy|Radiation:
Nonmetastatic Pancreatic
radiation therapy
Cancer That Cannot Be
Removed By Surgery

Allocation: Non-
Gemcitabine, Infusional 5 Randomized|Control:
Fluorouracil and Drug: Gemcitabine|Drug: Ohio State University Uncontrolled|Interventio
250 NCT00417976 Bevacizumab in Patients Recruiting Bevacizumab|Drug: Infusional 5- Comprehensive Phase II 39 n Model: Single Group 2-Jan-07 Dec-06 27-Dec-07 Dec-07 Dec-09
With Advanced Pancreas Fluorouracil Cancer Center Assignment|Masking:
Cancer Open Label|Primary
Purpose: Treatment

Drug: gemcitabine
Stereotactic Radiation
hydrochloride|Drug:
Therapy and Combination
oxaliplatin|Procedure: adjuvant
Chemotherapy in Treating Technische Masking: Open
therapy|Procedure: neoadjuvant
274 NCT00425841 Patients Undergoing Recruiting Universität Phase II 29 Label|Primary Purpose: 19-Jan-07 May-06 6-Feb-09 Jan-07
therapy|Radiation:
Surgery for Locally München Treatment
hypofractionated radiation
Advanced Pancreatic
therapy|Radiation: stereotactic
Cancer
radiosurgery

University of Intervention Model:


Gemcitabine and S-1 for
California, San Single Group
Locally Advanced Drug: S-1|Drug: gemcitabine
163 NCT00429858 Suspended Francisco|National Phase II 100 Assignment|Masking: 30-Jan-07 Jan-07 Dec-11 19-Feb-10 Jun-09 Dec-10
Unresectable or Metastatic hydrochloride
Cancer Institute Open Label|Primary
Pancreatic Cancer
(NCI) Purpose: Treatment

Combination
Chemotherapy and
Radiation Therapy Plus Active, not Drug: fluorouracil|Drug: National Cancer Primary Purpose:
101 NCT00020345 Phase II 2-Mar-07 Sep-00 2-Mar-07 Dec-01
Surgery in Treating recruiting gemcitabine Institute (NCI) Treatment
Patients With Advanced
Cancer of the Pancreas

Gemcitabine,
Biological: bevacizumab|Drug: Robert H. Lurie
Bevacizumab, and
gemcitabine Cancer Masking: Open
Abdominal Radiation Active, not
180 NCT00460174 hydrochloride|Procedure: Center|National Phase II 30 Label|Primary Purpose: 11-Apr-07 Oct-05 18-Apr-09 Jan-09 Oct-07
Therapy in Treating recruiting
conventional surgery|Radiation: Cancer Institute Treatment
Patients With Localized
radiation therapy (NCI)
Pancreatic Cancer

Gemcitabine With or
Without Dalteparin in Drug: dalteparin|Drug:
Hull and East Allocation:
Treating Patients With gemcitabine
207 NCT00462852 Recruiting Yorkshire Hospitals Phase II 120 Randomized|Primary 18-Apr-07 Apr-03 9-May-09 Apr-07
Locally Advanced or hydrochloride|Other: laboratory
NHS Trust Purpose: Treatment
Metastatic Pancreatic biomarker analysis
Cancer

28 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Drug: erlotinib
Roswell Park Cancer
Erlotinib in Treating hydrochloride|Other: Masking: Open
Active, not Institute|National
92 NCT00470535 Patients With Stage III or immunohistochemistry staining Phase II 34 Label|Primary Purpose: 3-May-07 Jan-07 15-Apr-09 Apr-09 May-11
recruiting Cancer Institute
Stage IV Pancreatic Cancer method|Other: laboratory Treatment
(NCI)
biomarker analysis

University of Intervention Model:


Erlotinib in Treating
California, Single Group
Patients With Pancreatic
171 NCT00482625 Recruiting Drug: Erlotinib Irvine|National Phase II 30 Assignment|Masking: 4-Jun-07 May-06 Dec-12 13-Apr-10 Apr-10 Dec-11
Cancer That Can Be
Cancer Institute Open Label|Primary
Removed by Surgery
(NCI) Purpose: Treatment

Drug: sirolimus|Genetic:
polymorphism analysis|Genetic:
reverse transcriptase-
polymerase chain Sidney Kimmel
reaction|Other: Comprehensive
Sirolimus in Treating
Active, not immunohistochemistry staining Cancer Primary Purpose:
137 NCT00499486 Patients With Advanced Phase II 50 10-Jul-07 Jan-05 7-Feb-09 Feb-09
recruiting method|Other: laboratory Center|National Treatment
Pancreatic Cancer
biomarker analysis|Other: liquid Cancer Institute
chromatography|Other: mass (NCI)
spectrometry|Other:
pharmacological
study|Procedure: biopsy

Gemcitabine With or
Without WX-671 in
Allocation:
Treating Patients With Drug: gemcitabine
Active, not Randomized|Masking:
129 NCT00499265 Locally Advanced hydrochloride|Drug: serine Wilex Phase II 90 10-Jul-07 Apr-07 22-Oct-08 Apr-08
recruiting Open Label|Primary
Pancreatic Cancer That protease inhibitor WX-671
Purpose: Treatment
Cannot Be Removed By
Surgery

Drug: gemcitabine
hydrochloride|Drug:
oxaliplatin|Genetic: protein
Gemcitabine and Memorial Sloan-
expression analysis|Genetic: Allocation: Non-
Oxaliplatin in Treating Kettering Cancer
proteomic profiling|Other: Randomized|Masking:
241 NCT00536874 Patients With Pancreatic Recruiting Center|National Phase II 37 27-Sep-07 Oct-07 7-Jul-09 Jul-09 Oct-10
laboratory biomarker Open Label|Primary
Cancer That Can Be Cancer Institute
analysis|Procedure: adjuvant Purpose: Treatment
Removed By Surgery (NCI)
therapy|Procedure: conventional
surgery|Procedure: neoadjuvant
therapy

Allocation:
Randomized|Endpoint
Classification:
Safety/Efficacy
Phase II Study to Evaluate Study|Intervention
Efficacy and Safety of Drug: RP101|Drug: Gemcitabine SciClone Model: Parallel
150 NCT00550004 Terminated Phase II 153 25-Oct-07 Sep-07 Oct-09 12-Oct-09 Oct-09 Aug-09
RP101 in Combination With (1000 mg/m2) Pharmaceuticals Assignment|Masking:
Gemcitabine Double Blind (Subject,
Caregiver,
Investigator)|Primary
Purpose: Health Services
29 of 47 4/20/2010, 8:16 PM
Research
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation: Non-
Randomized|Control:
Historical
Control|Endpoint
Vaccine Study for
Biological: HyperAcute(R)- NewLink Genetics Classification: Efficacy
290 NCT00569387 Surgically Resected Recruiting Phase II 71 5-Dec-07 Dec-07 Apr-10 12-Feb-10 Feb-10 Apr-10
Pancreatic Cancer Vaccine Corporation Study|Intervention
Pancreatic Cancer
Model: Single Group
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Allocation:
Randomized|Control:
Active Control|Endpoint
Classification: Efficacy
An Efficacy Study of Study|Intervention
Active, not Drug: MORAb-009|Drug:
261 NCT00570713 MORAb-009 in Subjects Morphotek Phase II 152 Model: Parallel 7-Dec-07 Dec-07 Mar-10 23-Mar-09 Mar-09
recruiting Gemcitabine
With Pancreatic Cancer Assignment|Masking:
Double Blind (Subject,
Investigator, Outcomes
Assessor)|Primary
Purpose: Treatment

Cetuximab and Radiation


Therapy in Treating
Biological: cetuximab|Radiation: Masking: Open
Patients With Locally Christie Hospital NHS
219 NCT00599833 Recruiting 3-dimensional conformal Phase II 44 Label|Primary Purpose: 11-Jan-08 May-07 21-Aug-09 Aug-09 May-12
Advanced Pancreatic Foundation Trust
radiation therapy Treatment
Cancer That Cannot Be
Removed by Surgery

Panitumumab,
Chemotherapy, and
Biological: panitumumab|Drug: North Central Cancer
External-Beam Radiation
capecitabine|Drug: Treatment Masking: Open
Therapy in Treating
177 NCT00601627 Recruiting fluorouracil|Drug: gemcitabine Group|National Phase II 50 Label|Primary Purpose: 18-Jan-08 Jun-09 10-Apr-10 Apr-10 Dec-09
Patients With Locally
hydrochloride|Radiation: Cancer Institute Treatment
Advanced Pancreatic
radiation therapy (NCI)
Cancer That Cannot be
Removed by Surgery

Paclitaxel Albumin-
Stabilized Nanoparticle
Formulation in Treating University of Miami
Drug: paclitaxel albumin- Masking: Open
Patients With Locally Active, not Sylvester
184 NCT00691054 stabilized nanoparticle Phase II 20 Label|Primary Purpose: 4-Jun-08 Jun-08 11-Jan-10 Jan-10 Jun-15
Advanced or Metastatic recruiting Comprehensive
formulation Treatment
Pancreatic Cancer That Did Cancer Center
Not Respond to First-Line
Therapy With Gemcitabine

Open, Randomized Phase


Endpoint Classification:
II Trial to Investigate the
Efficacy
Efficacy and Safety of the
Boehringer Ingelheim Study|Intervention
142 NCT00710710 PLK-1 Inhibitor BI 2536 in Completed Drug: BI 2536 Phase II 89 3-Jul-08 Aug-06 28-May-09 May-09 Oct-08
Pharmaceuticals Model: Parallel
Patients With Advanced,
Assignment|Primary
Unresectable Pancreatic
Purpose: Treatment
Cancer 30 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Drug: erlotinib
hydrochloride|Drug: sorafenib
Sorafenib and Erlotinib in Vanderbilt-Ingram
tosylate|Genetic: DNA Allocation: Non-
Treating Patients With Cancer
analysis|Genetic: gene Randomized|Masking:
193 NCT00837876 Pancreatic Cancer That Recruiting Center|National Phase II 47 5-Feb-09 Oct-08 24-Dec-09 Dec-09 Jun-15
expression analysis|Genetic: Open Label|Primary
Cannot Be Removed by Cancer Institute
polymorphism analysis|Genetic: Purpose: Treatment
Surgery (NCI)
proteomic profiling|Other:
laboratory biomarker analysis

Jonsson
Genistein in Treating Comprehensive Allocation:
Dietary Supplement:
Patients With Pancreatic Not yet Cancer Randomized|Masking:
242 NCT00882765 genistein|Procedure: therapeutic Phase II 30 15-Apr-09 Apr-09 8-Jan-10 Jun-09 Apr-10
Cancer That Can Be recruiting Center|National Open Label|Primary
conventional surgery
Removed by Surgery Cancer Institute Purpose: Treatment
(NCI)

Cisplatin, Capecitabine,
Gemcitabine Hydrochloride
Drug: capecitabine|Drug: Allocation:
and Epirubicin
cisplatin|Drug: docetaxel|Drug: Istituto Scientifico H. Randomized|Masking:
100 NCT00966706 Hydrochloride or Docetaxel Recruiting Phase II 104 26-Aug-09 Jun-05 29-Sep-09 Aug-09 Aug-08
epirubicin hydrochloride|Drug: San Raffaele Open Label|Primary
in Treating Patients With
gemcitabine hydrochloride Purpose: Treatment
Stage III or Stage IV
Pancreatic Cancer

Definitive Chemoradiation
With Gemcitabine and
Endpoint Classification:
Continuous Fluorouracil (5-
Safety/Efficacy
FU) Followed by High Dose
Drug: Gemcitabine|Drug: Study|Intervention
Rate Brachytherapy or
301 NCT00983541 Recruiting Fluorouracil (5-FU)|Radiation: University of Utah Phase II 12 Model: Single Group 22-Sep-09 Sep-09 Sep-11 19-Mar-10 Mar-10 Sep-11
Stereotactic Body
Brachytherapy or SBRT Assignment|Masking:
Radiation Therapy Boost in
Open Label|Primary
Locally Advanced Intra or
Purpose: Treatment
Extrahepatic
Cholangiocarcinoma

Temsirolimus and
Bevacizumab in Treating
Patients With Locally
Advanced, Recurrent, Biological: bevacizumab|Drug: Mayo Clinic|National Masking: Open
291 NCT01010126 Metastatic, or Progressive Recruiting temsirolimus|Other: laboratory Cancer Institute Phase II 275 Label|Primary Purpose: 6-Nov-09 Sep-09 2-Apr-10 Apr-10 Dec-12
Endometrial Cancer, biomarker analysis (NCI) Treatment
Ovarian Epithelial Cancer,
Liver Cancer, Islet Cell
Cancer, or Carcinoid Tumor

Gemcitabine, Capecitabine,
Drug: capecitabine|Drug:
and Radiation Therapy in
gemcitabine Allocation:
Treating Patients With
hydrochloride|Procedure: quality- Wales Cancer Trials Randomized|Masking:
167 NCT01032057 Locally Advanced Recruiting Phase II 102 13-Dec-09 Jul-09 13-Dec-09 Dec-09 Jul-11
of-life assessment|Radiation: 3- Unit Open Label|Primary
Pancreatic Cancer That
dimensional conformal radiation Purpose: Treatment
Cannot Be Removed by
therapy
Surgery

31 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Allocation: Non-
Randomized|Endpoint
Drug: Neoadjuvant gemcitabine, Classification:
Neoadjuvant GTX With
capecitabine, and Safety/Efficacy
Chemoradiation for
95 NCT01065870 Recruiting docetaxel|Drug: Gemcitabine, Columbia University Phase II 64 Study|Intervention 8-Feb-10 Dec-09 Dec-13 13-Apr-10 Apr-10 Dec-12
Pancreatic Cancer (Stage
capecitabine, docetaxel followed Model: Parallel
II/III)
by radiotherapy Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Combination
Chemotherapy Followed by Drug: cisplatin|Drug: New York University
Chemotherapy and gemcitabine School of
Active, not Phase I|Phase Primary Purpose:
149 NCT00003332 Radiation Therapy and/or hydrochloride|Procedure: Medicine|National 36 1-Nov-99 Jul-97 6-Feb-09 Apr-04
recruiting II Treatment
Surgery in Treating surgical procedure|Radiation: Cancer Institute
Patients Who Have radiation therapy (NCI)
Pancreatic Cancer

Endoscopic Placement of Robert H. Lurie


Metal Stents in Treating Procedure: bowel obstruction Cancer
Active, not Phase I|Phase Primary Purpose:
113 NCT00004910 Patients With Cancer- management|Procedure: quality- Center|National 7-Mar-00 Jan-00 9-May-09 May-00
recruiting II Supportive Care
Related Duodenal of-life assessment Cancer Institute
Obstruction (NCI)

Combination University of
Chemotherapy and Biological: bevacizumab|Drug: California, San Masking: Open
Phase I|Phase
299 NCT00227617 Bevacizumab in Treating Recruiting fluorouracil|Drug: leucovorin Francisco|National 102 Label|Primary Purpose: 26-Sep-05 Jun-05 14-Jan-10 Jan-07 Dec-09
II
Patients With Advanced calcium|Drug: oxaliplatin Cancer Institute Treatment
Neuroendocrine Tumors (NCI)

Allocation: Non-
Drug: Gemcitabine 1000 mg/m2 Royal Marsden NHS Randomized|Control:
Combining Erlotinib Plus
iv days 1, 8, 15 of a 28 day Foundation Uncontrolled|Endpoint
Bevacizumab and
cycle|Drug: Capecitabine orally Trust|Professor Classification: Efficacy
Gemcitabine Plus Active, not Phase I|Phase
136 NCT00260364 days 1 -21|Drug: Erlotinib 100 Cunningham's 40 Study|Intervention 29-Nov-05 Nov-05 Dec-09 5-Jan-10 Jan-10
Capecitabine to Treat recruiting II
mg orally days 1-28|Drug: Clinical Research Model: Single Group
Advanced Pancreatic
Bevacizumab 5 mg/kg Fund|Hoffmann-La Assignment|Masking:
Cancer
intravenously every 2 weeks Roche Open Label|Primary
Purpose: Treatment

AZD0530 and Gemcitabine


in Treating Patients With
Masking: Open
Locally Advanced or Active, not Drug: AZD0530|Drug: NCIC Clinical Trials Phase I|Phase
135 NCT00265876 60 Label|Primary Purpose: 14-Dec-05 Sep-05 5-Mar-10 Mar-10 Jun-09
Metastatic Pancreatic recruiting gemcitabine hydrochloride Group II
Treatment
Cancer That Cannot Be
Removed By Surgery

Imatinib Mesylate and


Robert H. Lurie
Gemcitabine in Treating
Drug: gemcitabine Cancer Masking: Open
Patients With Locally Phase I|Phase
236 NCT00281996 Completed hydrochloride|Drug: imatinib Center|National 43 Label|Primary Purpose: 24-Jan-06 Mar-05 23-Jul-08 Apr-06 May-06
Advanced, Metastatic, or II
mesylate Cancer Institute Treatment
Recurrent Pancreatic
(NCI)
Cancer

32 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Gemcitabine and
University of
Bevacizumab in Treating Biological: bevacizumab|Drug: Allocation: Non-
California, San
Patients With Pancreatic Active, not gemcitabine Phase I|Phase Randomized|Masking:
195 NCT00410774 Francisco|National 20 11-Dec-06 Jul-06 6-Feb-09 Aug-08 Oct-07
Cancer That Has Been recruiting hydrochloride|Procedure: II Open Label|Primary
Cancer Institute
Completely Removed By adjuvant therapy Purpose: Treatment
(NCI)
Surgery

Allocation: Non-
Randomized|Control:
Uncontrolled|Endpoint
A Phase I/II Study With
Biological: AVX701|Biological: Classification:
CEA(6D) VRP Vaccine in
Active, not AVX701|Biological: AlphaVax, Inc.|Duke Phase I|Phase Safety/Efficacy
109 NCT00529984 Patients With Advanced or 36 12-Sep-07 Sep-07 May-10 20-Aug-09 Aug-09 May-10
recruiting AVX701|Biological: University II Study|Intervention
Metastatic CEA-Expressing
AVX701|Biological: AVX701 Model: Single Group
Malignancies
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

3-Dimensional Conformal
Radiation Therapy, Arterial
Embolization, and Tumor Drug: poly ICLC|Procedure:
Cell Vaccine in Treating biopsy|Procedure: hepatic artery University of Masking: Open
Phase I|Phase
268 NCT00553683 Patients With Recruiting embolization|Radiation: 3- Medicine and 40 Label|Primary Purpose: 2-Nov-07 Oct-07 7-Jul-09 Jul-09 Oct-09
II
Unresectable, Recurrent, dimensional conformal radiation Dentistry New Jersey Treatment
or Metastatic Primary Liver therapy
Cancer or Pancreatic
Cancer

Control:
Uncontrolled|Endpoint
High Intensity Focused Classification: Safety
CMED HIFU
Ultrasound Tumor Procedure: High intensity Phase I|Phase Study|Intervention
245 NCT00637364 Suspended Development 5 12-Mar-08 Mar-08 12-Jan-09 Jan-09 Jul-10
Treatment for Pancreatic focused ultrasound, HIFU II Model: Single Group
Corporation
Cancer Pain Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Control:
Uncontrolled|Endpoint
Classification:
Phase I/II Trial of
Safety/Efficacy
Radiation, Avastin and Duke Phase I|Phase
230 NCT00735306 Recruiting Drug: Avastin and Tarceva 34 Study|Intervention 13-Aug-08 Jul-08 Dec-11 15-Sep-09 Sep-09 Dec-10
Tarceva for Pancreatic University|Genentech II
Model: Single Group
Adenocarcinoma
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Intensity-Modulated
Drug: gemcitabine
Radiation Therapy and Cancer Institute of
hydrochloride|Procedure: Allocation: Non-
Gemcitabine in Treating New Jersey|National Phase I|Phase
212 NCT00878657 Recruiting adjuvant therapy|Radiation: 50 Randomized|Primary 8-Apr-09 Apr-09 18-Apr-09 Apr-09 Mar-13
Patients With Locally Cancer Institute II
intensity-modulated radiation Purpose: Treatment
Advanced Pancreatic (NCI)
therapy
Cancer

33 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Conatumumab,
Gemcitabine
Biological: conatumumab|Drug: Radiation Therapy
Hydrochloride,
capecitabine|Drug: gemcitabine Oncology Masking: Open
Capecitabine, and Not yet Phase I|Phase
229 NCT01017822 hydrochloride|Radiation: 3- Group|National 89 Label|Primary Purpose: 20-Nov-09 Nov-09 26-Mar-10 Mar-10 Nov-10
Radiation Therapy in recruiting II
dimensional conformal radiation Cancer Institute Treatment
Treating Patients With
therapy (NCI)
Locally Advanced
Pancreatic Cancer

Biological: filgrastim|Drug:
High-Dose Combination carboplatin|Drug:
Chemotherapy Plus cisplatin|Drug: City of Hope Medical
Peripheral Stem Cell Active, not cyclophosphamide|Drug: Center|National Primary Purpose:
228 NCT00002854 Phase I 6 1-Nov-99 Dec-94 11-Jan-10 Jan-10
Transplantation in Treating recruiting etoposide|Drug: Cancer Institute Treatment
Patients With Advanced ifosfamide|Drug: mesna|Drug: (NCI)
Cancer paclitaxel|Procedure: peripheral
blood stem cell transplantation

Indium In 111 Yale


Pentetreotide in Treating Active, not Radiation: indium In 111 University|National Primary Purpose:
295 NCT00002947 Phase I 35 1-Nov-99 Oct-96 26-Apr-09 May-07
Patients With Refractory recruiting pentetreotide Cancer Institute Treatment
Cancer (NCI)

Memorial Sloan-
Gemcitabine Plus Radiation
Drug: gemcitabine Kettering Cancer
Therapy in Treating Primary Purpose:
153 NCT00003426 Completed hydrochloride|Radiation: Center|National Phase I 1-Nov-99 Apr-98 6-Feb-09 Jun-02
Patients With Pancreatic Treatment
radiation therapy Cancer Institute
Cancer
(NCI)

Radiation Therapy in University of


Drug: motexafin
Treating Patients With Bile Pittsburgh|National Primary Purpose:
157 NCT00003411 Completed gadolinium|Radiation: radiation Phase I 1-Nov-99 Nov-98 26-Dec-09 Apr-07
Duct, Gallbladder, or Cancer Institute Treatment
therapy
Pancreatic Cancer (NCI)

Irinotecan and Albert Einstein


Active, not Drug: capecitabine|Drug: Primary Purpose:
176 NCT00003867 Capecitabine in Treating College of Medicine Phase I 30 1-Nov-99 Mar-99 23-Jul-08 Apr-07
recruiting irinotecan hydrochloride Treatment
Patients With Solid Tumors of Yeshiva University

Radiation Therapy Plus Sidney Kimmel


Gadolinium Texaphyrin in Comprehensive
Drug: motexafin
Treating Patients With Cancer Primary Purpose:
178 NCT00003798 Completed gadolinium|Radiation: radiation Phase I 45 1-Nov-99 Apr-00 9-Mar-10 Mar-10
Cancer of the Pancreas Center|National Treatment
therapy
That Cannot Be Removed Cancer Institute
by Surgery (NCI)

Arthur G. James
Interleukin-12 and Cancer Hospital &
Trastuzumab in Treating Biological: recombinant Richard J. Solove
Primary Purpose:
168 NCT00004074 Patients With Cancer That Completed interleukin-12|Biological: Research Phase I 15 10-Dec-99 Jul-99 6-Feb-10 Mar-09 Feb-09
Treatment
Has High Levels of trastuzumab Institute|National
HER2/Neu Cancer Institute
(NCI)

Beth Israel
Gene Therapy in Treating Active, not Biological: therapeutic Primary Purpose:
172 NCT00004178 Deaconess Medical Phase I 21-Jan-00 Apr-98 6-Feb-09 May-06
Patients With Cancer recruiting autologous lymphocytes Treatment
Center

Duke
Biological Therapy in Biological: carcinoembryonic
Active, not University|National Primary Purpose:
217 NCT00004604 Treating Patients With antigen RNA-pulsed DC cancer Phase I 18 2-May-00 Feb-97 6-Feb-09 Apr-07
recruiting Cancer Institute 34 of 47 Treatment 4/20/2010, 8:16 PM
Metastatic Cancer vaccine
(NCI)
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

LMB-9 Immunotoxin in University of


Treating Patients With Maryland
Advanced Colon, Breast, Greenebaum Cancer Primary Purpose:
111 NCT00005858 Completed Biological: LMB-9 immunotoxin Phase I 2-Jun-00 Apr-00 6-Feb-09 Mar-03
Non-Small Cell Lung, Center|National Treatment
Bladder, Pancreatic, or Cancer Institute
Ovarian Cancer (NCI)

Trastuzumab Plus R115777 University of


in Treating Patients With Biological: trastuzumab|Drug: Texas|National Primary Purpose:
185 NCT00005842 Completed Phase I 2-Jun-00 Jun-00 29-Aug-09 Apr-07
Advanced or Metastatic tipifarnib Cancer Institute Treatment
Cancer (NCI)

H. Lee Moffitt Cancer


Yttrium Y 90 SMT 487 in
Center and Research
Treating Patients With Active, not Radiation: yttrium Y 90- Primary Purpose:
293 NCT00006368 Institute|National Phase I 4-Oct-00 Nov-99 6-Feb-09 Oct-01
Refractory or Recurrent recruiting edotreotide Treatment
Cancer Institute
Cancer
(NCI)

Immunotoxin Therapy in Masking: Open


Biological: SS1(dsFv)-PE38 National Cancer
110 NCT00006981 Treating Patients With Completed Phase I Label|Primary Purpose: 6-Dec-00 Dec-00 9-Jan-10 May-05
immunotoxin Institute (NCI)
Advanced Cancer Treatment

Vaccine Therapy in
University of
Treating Patients With
Active, not Biological: MUC-1 antigen/SB AS- Pittsburgh|National Primary Purpose:
174 NCT00008099 Resected or Locally Phase I 6-Jan-01 May-98 29-Jul-09 Apr-07
recruiting 2 Cancer Institute Treatment
Advanced Unresectable
(NCI)
Pancreatic Cancer

Capecitabine Combined New York University


With Cisplatin in Treating School of
Active, not Drug: capecitabine|Drug: Primary Purpose:
183 NCT00010023 Patients With Locally Medicine|National Phase I 2-Feb-01 Aug-00 23-Jul-08 Dec-05
recruiting cisplatin Treatment
Advanced or Metastatic Cancer Institute
Solid Tumors (NCI)

LMB-9 Immunotoxin in
University Hospital
Treating Patients With
Active, not Freiburg|National Primary Purpose:
120 NCT00010270 Advanced Pancreatic, Biological: LMB-9 immunotoxin Phase I 50 2-Feb-01 Apr-01 6-Feb-09 Jan-07
recruiting Cancer Institute Treatment
Esophageal, Stomach,
(NCI)
Colon, or Rectal Cancer

Combination
Norris Cotton Cancer
Chemotherapy Plus Biological: filgrastim|Drug:
Active, not Center|National Primary Purpose:
132 NCT00014456 Filgrastim in Treating docetaxel|Drug: gemcitabine Phase I 10-Apr-01 Mar-00 6-Feb-09 Nov-04
recruiting Cancer Institute Treatment
Patients With Advanced hydrochloride
(NCI)
Solid Tumors

MS-275 in Treating
Masking: Open
Patients With Advanced National Cancer
216 NCT00020579 Completed Drug: entinostat Phase I 75 Label|Primary Purpose: 11-Jul-01 Mar-01 13-Mar-10 Feb-07 Apr-08
Solid Tumors or Institute (NCI)
Treatment
Lymphoma

Jonsson
Comprehensive
SU006668 in Treating
Active, not Cancer Primary Purpose:
115 NCT00024063 Patients With Advanced Drug: SU6668 Phase I 13-Sep-01 16-Nov-08 Apr-07
recruiting Center|National Treatment
Solid Tumors
Cancer Institute
(NCI)

35 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

University of
Radiolabeled Monoclonal
California, San
Antibody Therapy in Other: iodine I 131 monoclonal Primary Purpose:
119 NCT00025532 Completed Francisco|National Phase I 11-Oct-01 Apr-01 6-Feb-09 Apr-07
Treating Patients With antibody CC49-deltaCH2 Treatment
Cancer Institute
Gastrointestinal Cancer
(NCI)

Ichor Medical
Electroporation Therapy
Biological: bleomycin Systems
With Bleomycin in Treating Active, not Primary Purpose:
170 NCT00027521 sulfate|Drug: electroporation Incorporated|Nationa Phase I 7-Dec-01 Dec-00 18-Apr-09 Jul-02
Patients With Pancreatic recruiting Treatment
therapy l Cancer Institute
Cancer
(NCI)

Biological: CMV pp65


Vaccine Therapy in peptide|Biological: recombinant Duke
Treating Patients With fowlpox-CEA(6D)/TRICOM University|National Primary Purpose:
117 NCT00027534 Completed Phase I 7-Dec-01 Jan-02 6-Feb-09 Sep-05
Advanced or Metastatic vaccine|Biological: tetanus Cancer Institute Treatment
Cancer toxoid|Biological: therapeutic (NCI)
autologous dendritic cells

Vaccine Therapy With or Biological: recombinant fowlpox


Fox Chase Cancer
Without Sargramostim in GM-CSF vaccine
Center|National Primary Purpose:
118 NCT00028496 Treating Patients With Completed adjuvant|Biological: recombinant Phase I 4-Jan-02 Jan-02 6-Feb-09 Aug-03
Cancer Institute Treatment
Advanced or Metastatic fowlpox-CEA(6D)/TRICOM
(NCI)
Cancer vaccine|Biological: sargramostim

Erlotinib in Treating Cancer and Leukemia


Patients With Solid Tumors Group B|National Primary Purpose:
223 NCT00030498 Completed Drug: erlotinib hydrochloride Phase I 14-Feb-02 Dec-01 10-Sep-09 Dec-08 Jul-07
and Liver or Kidney Cancer Institute Treatment
Dysfunction (NCI)

Erlotinib Combined With


Gemcitabine in Treating
Patients With Newly Drug: erlotinib
Primary Purpose:
148 NCT00033241 Diagnosed Locally Completed hydrochloride|Drug: gemcitabine OSI Pharmaceuticals Phase I 9-Apr-02 Jun-01 23-Jul-08 Dec-03
Treatment
Advanced or Metastatic hydrochloride
Pancreatic Cancer or Other
Solid Tumors

M.D. Anderson
UCN-01 and Gemcitabine
Drug: 7- Cancer
in Treating Patients With Primary Purpose:
156 NCT00039403 Completed hydroxystaurosporine|Drug: Center|National Phase I 6-Jun-02 May-02 23-Jul-08 Jan-06
Unresectable or Metastatic Treatment
gemcitabine hydrochloride Cancer Institute
Pancreatic Cancer
(NCI)

Flavopiridol Plus Radiation


Memorial Sloan-
Therapy Followed By Drug: alvocidib|Drug:
Kettering Cancer
Gemcitabine in Treating gemcitabine Primary Purpose:
143 NCT00047307 Completed Center|National Phase I 46 3-Oct-02 Aug-02 6-Feb-09 Mar-08 Aug-08
Patients With Locally hydrochloride|Radiation: Treatment
Cancer Institute
Advanced, Unresectable radiation therapy
(NCI)
Pancreatic Cancer

Holden
Radiolabeled Octreotide in Comprehensive
Treating Children With Radiation: yttrium Y 90- Cancer Primary Purpose:
298 NCT00049023 Recruiting Phase I 35 12-Nov-02 Jan-02 6-Feb-09 Apr-08
Advanced or Refractory edotreotide Center|National Treatment
Solid Tumors Cancer Institute
(NCI) 36 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

National Center for


Gemcitabine Combined Complementary and
Dietary Supplement: mistletoe Masking: Open
With Mistletoe in Treating Active, not Alternative Medicine
121 NCT00049608 extract|Drug: gemcitabine Phase I 51 Label|Primary Purpose: 12-Nov-02 Jul-02 6-Feb-09 Apr-07
Patients With Advanced recruiting (NCCAM)|National
hydrochloride Treatment
Solid Tumors Cancer Institute
(NCI)

Case Comprehensive Intervention Model:


Thalidomide and Docetaxel Cancer Single Group
Drug: docetaxel|Drug:
194 NCT00049296 in Treating Patients With Completed Center|National Phase I 26 Assignment|Masking: 12-Nov-02 Jul-02 Jan-06 23-Feb-10 Feb-10 Dec-04
thalidomide
Advanced Cancer Cancer Institute Open Label|Primary
(NCI) Purpose: Treatment

Erlotinib, Gemcitabine, and


Memorial Sloan-
Radiation Therapy in Drug: erlotinib
Kettering Cancer Masking: Open
Treating Patients With hydrochloride|Drug: gemcitabine
209 NCT00063947 Completed Center|National Phase I 28 Label|Primary Purpose: 8-Jul-03 Jun-03 11-Feb-09 Nov-06 Jan-09
Locally Advanced hydrochloride|Radiation:
Cancer Institute Treatment
Unresectable Pancreatic radiation therapy
(NCI)
Cancer

Tipifarnib and Radiation


University of
Therapy in Treating
Active, not Drug: tipifarnib|Radiation: Pennsylvania|Nationa Primary Purpose:
222 NCT00077519 Patients With Unresectable Phase I 18 10-Feb-04 Jan-04 6-Feb-09 Apr-07
recruiting radiation therapy l Cancer Institute Treatment
Locally Advanced
(NCI)
Pancreatic Cancer

Erlotinib and Cetuximab


With or Without
Bevacizumab in Treating Biological: Institute for Drug
Masking: Open
Patients With Metastatic or bevacizumab|Biological: Development|Nationa
112 NCT00101348 Completed Phase I 66 Label|Primary Purpose: 7-Jan-05 Jan-05 6-Feb-09 Nov-06 Jul-08
Unresectable Kidney, cetuximab|Drug: erlotinib l Cancer Institute
Treatment
Colorectal, Head and Neck, hydrochloride (NCI)
Pancreatic, or Non-Small
Cell Lung Cancer

Allocation: Non-
Randomized|Control:
Dose
Comparison|Endpoint
Evaluation of Safety of Genetic: Rexin-G Dose
Classification:
Rexin-G Gene Transfer for 1|Genetic: Rexin-G Dose Epeius
288 NCT00121745 Terminated Phase I 12 Safety/Efficacy 15-Jul-05 Jul-05 Jul-07 15-Dec-07 Dec-07
Advanced Pancreatic 2|Genetic: Rexin-G Dose Biotechnologies
Study|Intervention
Cancer 3|Genetic: Rexin-G Dose 4
Model: Single Group
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Oxaliplatin, Gemcitabine,
UNC Lineberger
Erlotinib, and Radiation Drug: erlotinib Allocation: Non-
Comprehensive
Therapy in Treating hydrochloride|Drug: gemcitabine Randomized|Control:
Active, not Cancer
247 NCT00266097 Patients With Unresectable hydrochloride|Drug: Phase I 110 Uncontrolled|Masking: 13-Dec-05 Aug-04 26-Nov-09 Nov-09 Mar-09
recruiting Center|National
and/or Metastatic oxaliplatin|Radiation: radiation Open Label|Primary
Cancer Institute
Pancreatic Cancer or Biliary therapy Purpose: Treatment
(NCI)
Tract Cancer

37 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Arthur G. James
3-AP and Radiation
Cancer Hospital &
Therapy in Treating
Richard J. Solove
Patients With Stage III Drug: triapine|Radiation: Primary Purpose:
102 NCT00288093 Recruiting Research Phase I 30 6-Feb-06 Dec-06 2-Feb-10 Jun-07 Aug-07
Pancreatic Cancer That radiation therapy Treatment
Institute|National
Cannot Be Removed By
Cancer Institute
Surgery
(NCI)

Pemetrexed, Gemcitabine,
Drug: gemcitabine Wake Forest Allocation: Non-
and Radiation Therapy in
hydrochloride|Drug: pemetrexed University|National Randomized|Masking:
203 NCT00310050 Treating Patients With Completed Phase I 33 29-Mar-06 Oct-05 6-Feb-09 Apr-08 May-08
disodium|Radiation: radiation Cancer Institute Open Label|Primary
Locally Advanced
therapy (NCI) Purpose: Treatment
Pancreatic Cancer

Allocation: Non-
Randomized|Endpoint
Maytansinoid DM4- Classification:
Conjugated Humanized Safety/Efficacy
186 NCT00352131 Monoclonal Antibody Completed Drug: HuC242-DM4 ImmunoGen, Inc. Phase I 50 Study|Intervention 13-Jul-06 Feb-05 Dec-09 16-Mar-10 Mar-10 Dec-09
huC242 in Treating Model: Single Group
Patients With Solid Tumors Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Vaccine Therapy in
Treating Patients With Drug: Detox-B adjuvant|Drug: National Cancer Primary Purpose:
89 NCT00019006 Completed Phase I 1-Mar-07 Mar-95 1-Mar-07 May-05
Colon, Pancreatic, or Lung ras peptide cancer vaccine Institute (NCI) Treatment
Cancer

Endpoint Classification:
Case Comprehensive Safety/Efficacy
Sunitinib and Gemcitabine
Drug: gemcitabine Cancer Study|Intervention
in Treating Patients With Active, not
175 NCT00462553 hydrochloride|Drug: sunitinib Center|National Phase I 37 Model: Single Group 18-Apr-07 Mar-07 13-Apr-10 Apr-10 Mar-10
Pancreatic Cancer or Other recruiting
malate Cancer Institute Assignment|Masking:
Solid Tumors
(NCI) Open Label|Primary
Purpose: Treatment

Gemcitabine, Cetuximab,
and Radiation Therapy in Vanderbilt-Ingram
Biological: cetuximab|Drug:
Treating Patients With Cancer
Active, not gemcitabine Primary Purpose:
243 NCT00467116 Locally Advanced Center|National Phase I 30 25-Apr-07 Oct-05 6-Feb-09 Oct-08 Oct-10
recruiting hydrochloride|Radiation: Treatment
Pancreatic Cancer That Cancer Institute
radiation therapy
Cannot Be Removed by (NCI)
Surgery

Allocation:
Randomized|Endpoint
Study to Assess the Safety Classification:
& Tolerability of a PARP Drug: KU-0059436 AstraZeneca|KuDOS Safety/Efficacy
Active, not
273 NCT00515866 Inhibitor in Combination (AZD2281)(PARP Pharmaceuticals Phase I 95 Study|Intervention 13-Aug-07 Aug-07 Aug-10 12-Apr-10 Apr-10 Aug-10
recruiting
With Gemcitabine in inhibitor)|Drug: Gemcitabine Limited Model: Parallel
Pancreatic Cancer Assignment|Masking:
Open Label|Primary
Purpose: Treatment

38 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Drug: gemcitabine
hydrochloride|Genetic:
polymerase chain
Gemcitabine and Radiation
reaction|Other: City of Hope Medical
Therapy in Treating
Active, not immunohistochemistry staining Center|National Primary Purpose:
138 NCT00544193 Patients With Locally Phase I 15 13-Oct-07 Dec-97 13-Jan-10 Jan-10
recruiting method|Procedure: conventional Cancer Institute Treatment
Advanced Upper
surgery|Radiation: (NCI)
Gastrointestinal Cancer
intraoperative radiation
therapy|Radiation: radiation
therapy

Positron Emission
Other: high performance liquid
Tomography Using [18F]-
chromatography|Other: Allocation: Non-
Labeled Substance P
pharmacological National Cancer Randomized|Control:
134 NCT00547612 Antagonist Receptor Completed Phase I 33 19-Oct-07 Sep-07 7-Feb-09 Nov-08 Dec-08
study|Radiation: [18F]-labeled Institute (NCI) Uncontrolled|Primary
Quantifier in Finding
substance P antagonist receptor Purpose: Diagnostic
Disease in Patients With
quantifier
Pancreatic Cancer

Allocation: Non-
Randomized|Control:
Dose
Combination Study of
Comparison|Endpoint
Capecitabine and Erlotinib
Classification:
Concurrent With Penn State
266 NCT00565487 Recruiting Drug: Capecitabine, Tarceva Phase I 27 Safety/Efficacy 29-Nov-07 Dec-07 Dec-10 9-Feb-10 Feb-10 Jan-10
Radiotherapy for Non- University|Genentech
Study|Intervention
Operable Advanced
Model: Single Group
Pancreatic Cancer
Assignment|Masking:
Open Label|Primary
Purpose: Treatment

Drug: fluorouracil|Drug:
Irinotecan, Fluorouracil, irinotecan hydrochloride|Drug:
Mayo Clinic|National
and Leucovorin in Treating leucovorin calcium|Other: Primary Purpose:
106 NCT00654160 Recruiting Cancer Institute Phase I 70 4-Apr-08 Jun-08 4-Aug-09 Aug-09 Jun-15
Patients With Advanced pharmacogenomic Treatment
(NCI)
Gastrointestinal Cancer studies|Other: pharmacological
study

Vaccine Therapy and GM-


CSF in Treating Patients Cancer Institute of
Biological: falimarev|Biological:
With Locally Advanced or New Jersey|National Primary Purpose:
188 NCT00669734 Recruiting inalimarev|Biological: Phase I 18 29-Apr-08 Feb-10 4-Feb-10 Aug-08 Aug-10
Metastatic Pancreatic Cancer Institute Treatment
sargramostim
Cancer That Cannot Be (NCI)
Removed By Surgery

Control:
Uncontrolled|Endpoint
Safety Study of XL147 in Classification: Safety
Combination With Erlotinib Study|Intervention
300 NCT00692640 Recruiting Drug: XL147|Drug: Erlotinib Exelixis Phase I 65 3-Jun-08 May-08 Oct-09 20-Oct-08 Oct-08 Oct-09
in Adults With Solid Model: Single Group
Tumors Assignment|Masking:
Open Label|Primary
Purpose: Treatment

39 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Intervention Model:
Phase I Study of Docetaxel
Washington Single Group
and Temsirolimus in Active, not
57 NCT00703625 Drug: temsirolimus & docetaxel University School of Phase I 25 Assignment|Masking: 20-Jun-08 Mar-08 15-Sep-09 Sep-09 Mar-10
Resistant Solid recruiting
Medicine Open Label|Primary
Malignancies
Purpose: Treatment

Masonic Cancer
Sorafenib, Pemetrexed,
Drug: cisplatin|Drug: Center, University of
and Cisplatin in Treating Primary Purpose:
130 NCT00703638 Recruiting pemetrexed disodium|Drug: Minnesota|National Phase I 12 20-Jun-08 May-08 4-Mar-10 Mar-10 Jun-11
Patients With Advanced Treatment
sorafenib tosylate Cancer Institute
Solid Tumors
(NCI)

Allocation: Non-
A Pilot Study Assessing
Randomized|Endpoint
Intra-Metastasis
Classification:
Administration of Radiation: tumoral
University of Safety/Efficacy
Autologous KLH-pulsed irradiation|Biological: Dendritic
83 NCT00843830 Suspended Michigan Cancer Phase I 6 Study|Intervention 12-Feb-09 Oct-06 Jun-15 19-Feb-10 Feb-10 Jun-14
Dendritic Cells With cell vaccination|Biological:
Center Model: Single Group
Tumoral Radiation Therapy Additional cycles
Assignment|Masking:
in Patients With Metastatic
Open Label|Primary
Pancreatic Carcinoma
Purpose: Treatment

Gemcitabine, Capecitabine,
Drug: capecitabine|Drug: Allocation: Non-
and Erlotinib in Treating Centre Antoine
239 NCT00885066 Recruiting erlotinib hydrochloride|Drug: Phase I 30 Randomized|Primary 18-Apr-09 May-08 23-Dec-09 Jul-09 Mar-10
Patients With Advanced Lacassagne
gemcitabine hydrochloride Purpose: Treatment
Pancreatic Cancer

Drug: capecitabine|Drug: Vanderbilt-Ingram


Capecitabine, Vorinostat, vorinostat|Other: laboratory Cancer
and Radiation Therapy in biomarker analysis|Procedure: Center|National
Primary Purpose:
160 NCT00983268 Treating Patients With Recruiting diffusion-weighted magnetic Cancer Institute Phase I 15 23-Sep-09 Oct-09 4-Nov-09 Oct-09 May-15
Treatment
Nonmetastatic Pancreatic resonance imaging|Radiation: (NCI)|National
Cancer hypofractionated radiation Comprehensive
therapy Cancer Network

Gemcitabine
Hydrochloride, Oxaliplatin,
Drug: erlotinib Vanderbilt-Ingram
and Erlotinib Hydrochloride
hydrochloride|Drug: gemcitabine Cancer
in Treating Patients With Primary Purpose:
200 NCT00987766 Recruiting hydrochloride|Drug: Center|National Phase I 46 30-Sep-09 Nov-09 17-Nov-09 Nov-09 Jan-16
Advanced Biliary Tract Treatment
oxaliplatin|Other: laboratory Cancer Institute
Cancer, Pancreatic Cancer,
biomarker analysis (NCI)
Duodenal Cancer, or
Ampullary Cancer

Stereotactic Body
Radiation Therapy With or
Drug: gemcitabine
Without Gemcitabine
hydrochloride|Radiation: Simmons Cancer Primary Purpose:
224 NCT01025882 Hydrochloride in Treating Recruiting Phase I 30 3-Dec-09 Oct-09 3-Dec-09 Oct-09 Oct-14
stereotactic body radiation Center Treatment
Patients With Pancreatic
therapy
Cancer That Can Be
Removed By Surgery

40 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Drug: gemcitabine
hydrochloride|Drug: leucovorin
calcium|Drug: fluorouracil|Drug:
Stereotactic Radiation nelfinavir mesylate|Radiation:
Endpoint Classification:
Therapy, Nelfinavir stereotactic body radiation
Safety
Mesylate, Gemcitabine therapy|Radiation:
Study|Intervention
Hydrochloride, Leucovorin hypofractionated radiation University of
104 NCT01068327 Recruiting Phase I 36 Model: Single Group 25-Jan-10 Nov-07 30-Mar-10 Mar-10 Dec-12
Calcium, and Fluorouracil therapy|Procedure: therapeutic Nebraska
Assignment|Masking:
in Treating Patients With conventional surgery|Other:
Open Label|Primary
Locally Advanced pharmacological study|Genetic:
Purpose: Treatment
Pancreatic Cancer polymorphism analysis|Other:
pharmacogenomic
studies|Genetic: protein
expression analysis

A Study of TS-1, Cisplatin


Not yet Drug: TS-ONE, Cisplatin, National University
116 NCT01096199 (CDDP) and RAD001 Phase I 35 29-Mar-10 30-Mar-10 Mar-10
recruiting RAD001 Hospital, Singapore
(Everolimus)

Gemcitabine Compared Herbert Irving


With Pancreatic Enzyme Comprehensive
Therapy Plus Specialized Biological: proteolytic Cancer
Masking: Open
Diet (Gonzalez Regimen) in Active, not enzymes|Drug: gemcitabine Center|National
126 NCT00003851 90 Label|Primary Purpose: 1-Nov-99 Mar-99 15-Sep-09 Dec-05
Treating Patients Who recruiting hydrochloride|Procedure: Center for
Treatment
Have Stage II, Stage III, Gonzalez regimen Complementary and
or Stage IV Pancreatic Alternative Medicine
Cancer (NCCAM)

Procedure: management of
University of
Conventional Care With or therapy
Michigan Cancer
Without Specialized Cancer Active, not complications|Procedure: Primary Purpose:
269 NCT00006253 Center|National 11-Sep-00 Aug-00 19-Aug-09 Apr-07
Care in Treating Patients recruiting psychosocial assessment and Supportive Care
Cancer Institute
Receiving Chemotherapy care|Procedure: quality-of-life
(NCI)
assessment

Fluorouracil, External-
Beam Radiation Therapy,
and Gemcitabine With or Drug: fluorouracil|Drug:
Without Brachytherapy gemcitabine Allocation:
Using Phosphorus P32 in Active, not hydrochloride|Radiation: University of South Randomized|Control:
272 NCT00079365 8-Mar-04 May-01 6-Feb-09 May-05
Treating Patients With recruiting brachytherapy|Radiation: Florida Active Control|Primary
Locally or Regionally phosphorus P32|Radiation: Purpose: Treatment
Advanced Unresectable radiation therapy
Adenocarcinoma of the
Pancreas

EF5 and Motexafin


University of
Lutetium in Detecting Masking: Open
Drug: EF5|Drug: motexafin Pennsylvania|Nationa
284 NCT00087191 Tumor Cells in Patients Completed Label|Primary Purpose: 8-Jul-04 May-04 23-Jul-08 Dec-05
lutetium l Cancer Institute
With Abdominal or Non- Diagnostic
(NCI)
Small Cell Lung Cancer

41 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Early Intervention
Palliative Care or a
Other: counseling
Standard Palliative Care
intervention|Other: educational Norris Cotton Cancer
Program in Improving End-
Active, not intervention|Procedure: Center|National
281 NCT00253383 of-Life Care in Patients 450 Allocation: Randomized 11-Nov-05 Jan-03 12-Sep-09 Nov-08 Jun-08
recruiting psychosocial assessment and Cancer Institute
With Advanced Lung,
care|Procedure: quality-of-life (NCI)
Gastrointestinal,
assessment
Genitourinary, or Breast
Cancer

Case Comprehensive
Changes in Muscle Tissue Cancer Observational Model:
277 NCT00369460 in Patients With Pancreatic Completed Other: physiologic testing Center|National 9 Cohort|Time Perspective: 24-Aug-06 Jan-06 Jul-09 16-Apr-10 Apr-10 Jul-09
Cancer Cancer Institute Prospective
(NCI)

Other: biologic sample


Skin Biopsies and DNA Barbara Ann
preservation procedure|Other:
Analysis in Patients Karmanos Cancer
immunohistochemistry staining
258 NCT00369109 Receiving Irinotecan or Completed Institute|National 60 24-Aug-06 Feb-06 9-May-09 Mar-07
method|Other: laboratory
Gemcitabine For Advanced Cancer Institute
biomarker analysis|Procedure:
Solid Tumors (NCI)
biopsy

Aprepitant in Preventing Drug: aprepitant|Drug:


Allocation: Non-
Nausea and Vomiting in capecitabine|Drug: Wake Forest
Randomized|Masking:
Patients Undergoing Active, not fluorouracil|Drug: gemcitabine University|National
265 NCT00398164 57 Open Label|Primary 9-Nov-06 Aug-06 22-Dec-09 Oct-09 Jan-09
Chemotherapy and recruiting hydrochloride|Procedure: quality- Cancer Institute
Purpose: Supportive
Radiation Therapy for of-life assessment|Radiation: (NCI)
Care
Pancreatic Cancer radiation therapy

Other: clinical
Incidence of Blood Clots in European
observation|Procedure:
Patients Undergoing Active, not Organization for
263 NCT00433602 management of therapy 2000 8-Feb-07 Nov-06 13-Dec-09 Apr-07
Chemotherapy for Solid recruiting Research and
complications|Procedure:
Tumors Treatment of Cancer
ultrasound imaging

Biological: colloidal gold-bound


Tumor Necrosis Factor in tumor necrosis factor|Other:
Patients Undergoing electron microscopy|Other: National Cancer Primary Purpose:
232 NCT00436410 Completed 108 15-Feb-07 Dec-06 27-Aug-09 Nov-08 Aug-09
Surgery for Primary Cancer pharmacological Institute (NCI) Treatment
or Metastatic Cancer study|Procedure: conventional
surgery

Cetuximab, Gemcitabine,
University of Miami Allocation: Non-
and Oxaliplatin in Treating Biological: cetuximab|Drug:
Active, not Sylvester Randomized|Masking:
267 NCT00448838 Patients With Locally gemcitabine hydrochloride|Drug: 40 15-Mar-07 May-06 11-Jan-10 Jan-10 May-13
recruiting Comprehensive Open Label|Primary
Advanced or Metastatic oxaliplatin
Cancer Center Purpose: Treatment
Pancreatic Cancer

Genetic: DNA methylation


Biomarkers and Radiation analysis|Genetic: mutation
Side Effects in Patients analysis|Genetic: polymerase
National Cancer Primary Purpose:
218 NCT00452946 Undergoing Radiation Recruiting chain reaction|Other: laboratory 120 27-Mar-07 Feb-07 22-Dec-09 Jun-09
Institute (NCI) Supportive Care
Therapy for biomarker analysis|Procedure:
Gastrointestinal Cancer assessment of therapy
complications 42 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Making Decisions About


Other: counseling
Participating in a Cancer Sidney Kimmel
intervention|Other: study of
Clinical Trial for Patients Comprehensive
socioeconomic and demographic Masking: Open
With Stage II, Stage III, or Active, not Cancer
87 NCT00478010 variables|Procedure: 200 Label|Primary Purpose: 23-May-07 Jan-07 20-Jul-09 Feb-09 Dec-08
Stage IV Pancreatic Cancer recruiting Center|National
psychosocial assessment and Health Services Research
or Stage III or Stage IV Cancer Institute
care|Procedure: quality-of-life
Colon Cancer or Rectal (NCI)
assessment
Cancer

Drug: isosulfan blue|Other:


Visceral Lymphatic immunohistochemistry staining
Mapping Using Isosulfan method|Other: laboratory Wake Forest
Blue in Patients With Active, not biomarker analysis|Procedure: University|National Primary Purpose:
213 NCT00489515 125 20-Jun-07 Feb-99 18-Sep-09 Sep-09 Dec-10
Cancer of the Pancreas, recruiting conventional surgery|Procedure: Cancer Institute Diagnostic
Colon, Stomach, Small lymphadenectomy|Procedure: (NCI)
Intestine, or Gallbladder lymphangiography|Procedure:
sentinel lymph node biopsy

Sidney Kimmel
Cyclophosphamide and
Drug: cyclophosphamide|Other: Comprehensive
Cryoablation in Treating
laboratory biomarker Cancer Primary Purpose:
289 NCT00499733 Patients With Advanced or Recruiting 23 10-Jul-07 Jun-07 3-Jul-09 Jul-09 Jul-10
analysis|Procedure: Center|National Treatment
Metastatic Epithelial
biopsy|Procedure: cryosurgery Cancer Institute
Cancer
(NCI)

43 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Oncoscience
AG|Marienhospital
Herne, Abt. für
Hämatologie und
Onkologie, Herne,
Germany|University
of
Kiel|Gemeinschaftspr
axis für
Hämatologie und
Onkologie, Köln,
Germany|Onkologisc
hes Zentrum III,
Medizinische Klinik,
Mannheim,
Germany|Onkologisc
Observational Model:
Nimotuzumab in Adults he
297 NCT00561990 Recruiting 188 Case Control|Time 20-Nov-07 Sep-07 Sep-10 3-Feb-10 Feb-10
With Pancreatic Cancer Gemeinschaftspraxis,
Perspective: Prospective
Mülheim,
Germany|II.
Medizinische Klinik u.
Poliklinik, Klinikum
rechts der Isar,
München,
Germany|Hämatolo
gisch-Onkologische
Schwerpunktpraxis,
Münster,
Germany|Praxis für
Internistische
Onkologie und
Hämatologie,
Recklinghausen,
Germany

CBT-1 and Paclitaxel in


Treating Patients With Drug: MDR modulator CBT-
National Cancer Primary Purpose:
260 NCT00658424 Refractory, Recurrent, or Recruiting 1|Drug: paclitaxel|Radiation: Tc 12 12-Apr-08 Sep-07 6-Feb-09 Apr-08 Sep-08
Institute (NCI) Treatment
Advanced Metastatic Solid 99m sestamibi
Tumors

Drug: bupivacaine
Standard Pain Control or Sidney Kimmel
hydrochloride|Drug: Allocation:
Intrathecal Therapy in Comprehensive
clonidine|Drug: morphine Randomized|Masking:
Controlling Pain in Patients Cancer
275 NCT00660348 Suspended sulfate|Procedure: assessment 80 Open Label|Primary 16-Apr-08 Mar-08 6-Nov-09 Jul-09 Dec-10
With Locally Advanced, Center|National
of therapy Purpose: Supportive
Unresectable, or Metastatic Cancer Institute
complications|Procedure: quality- Care
Pancreatic Cancer (NCI)
of-life assessment

44 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Computer Tools for


Improving Early Diagnosis
and Treatment in Healthy Other: medical chart
University of
Volunteers or Patients With review|Other: questionnaire
Nebraska|National
271 NCT00661882 Pancreatic Cancer or Who Recruiting administration|Other: study of 240 18-Apr-08 Feb-03 16-Jun-09 Jun-09 Dec-12
Cancer Institute
Are At Risk For Pancreatic socioeconomic and demographic
(NCI)
Cancer or Who Have a variables|Procedure: biopsy
Noncancer Pancreatic
Disorder

Disease Management
Allocation: Non-
Program or Usual Care in
Case Comprehensive Randomized|Intervention
Patients With Stage III or
Other: questionnaire Cancer Model: Parallel
Stage IV Lung Cancer,
162 NCT00684801 Recruiting administration|Procedure: Center|National 744 Assignment|Masking: 23-May-08 Aug-07 16-Apr-10 Apr-10 Nov-10
Pancreatic Cancer, Ovarian
quality-of-life assessment Cancer Institute Open Label|Primary
Cancer, or Colorectal
(NCI) Purpose: Supportive
Cancer, and Their
Care
Caregivers

Other: counseling
intervention|Other: educational
intervention|Other:
Cognitive and Behavioral Massachusetts
questionnaire
Therapy or Standard Care General Allocation:
administration|Procedure:
287 NCT00706290 in Patients With Advanced Recruiting Hospital|National 60 Randomized|Control: 26-Jun-08 Apr-07 14-Jul-09 Jul-09 Mar-10
meditation therapy|Procedure:
Gastrointestinal Cancer or Cancer Institute Active Control
psychosocial assessment and
Lung Cancer (NCI)
care|Procedure: quality-of-life
assessment|Procedure: standard
follow-up care

Behavioral: compliance
monitoring|Dietary Supplement:
dietary intervention|Dietary
Supplement: nutritional
intervention|Drug:
Medical Nutrition Therapy chemotherapy|Other: counseling University of
or Standard Care in intervention|Other: medical Medicine and Allocation:
Treating Patients With chart review|Other: Dentistry New Randomized|Primary
99 NCT00769652 Terminated 230 8-Oct-08 Oct-06 Aug-09 10-Dec-09 Dec-09 Aug-09
Lung Cancer, Pancreatic questionnaire Jersey|National Purpose: Supportive
Cancer, or Stage III or administration|Other: study of Cancer Institute Care
Stage IV Prostate Cancer socioeconomic and demographic (NCI)
variables|Procedure:
management of therapy
complications|Procedure:
observation|Procedure: quality-
of-life assessment

A Phase III Second Line CONKO-


Trial in Advanced Approved for Studiengruppe|Sanofi-
50 NCT00786058 Drug: OFF in experimental arm 4-Nov-08 12-Jun-09 Jun-09
Pancreatic Cancer CONKO marketing Aventis|medac
003 GmbH|Amgen

Collecting Medical
Other: medical chart
Information and Tissue Mayo Clinic|National
review|Other: survey
257 NCT00830557 Samples From Patients Recruiting Cancer Institute 5000 27-Jan-09 Oct-00 16-Mar-10 Dec-08
administration|Procedure: study
With Pancreatic Cancer or (NCI) 45 of 47 4/20/2010, 8:16 PM
of high risk factors
Other Pancreatic Disorders
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Psychological and
Emotional Impact in Other: questionnaire
Patients Undergoing administration|Procedure:
Centre Oscar
74 NCT00896467 Treatment For Metastatic Recruiting psychosocial assessment and 200 8-May-09 Sep-07 7-Jul-09 Jul-09 Sep-10
Lambret
Cancer Either in a Clinical care|Procedure: quality-of-life
Trial or as Standard Off- assessment
Trial Therapy

Genetic: protein expression


analysis|Other: laboratory Barbara Ann
Identification of
biomarker analysis|Other: mass Karmanos Cancer
Biomarkers for Early Active, not
285 NCT00897494 spectrometry|Other: surface- Institute|National 120 9-May-09 Feb-05 17-Nov-09 Nov-09
Detection of Pancreatic recruiting
enhanced laser Cancer Institute
Cancer
desorption/ionization-time of (NCI)
flight mass spectrometry

Sidney Kimmel
Collecting and Storing
Comprehensive
Samples of Blood From Other: physiologic testing|Other:
Active, not Cancer
254 NCT00898482 Patients With Pancreatic study of socioeconomic and 400 9-May-09 May-05 5-Nov-09 Jul-09 Dec-10
recruiting Center|National
Cancer and Healthy demographic variables
Cancer Institute
Participants
(NCI)

Case Comprehensive
Biological Markers in Other: immunologic Observational Model:
Cancer
Patients With Pancreatic technique|Other: laboratory Case-Only|Time
278 NCT00899158 Completed Center|National 44 9-May-09 Jun-05 Dec-08 16-Apr-10 Apr-10 Nov-08
Cancer Experiencing biomarker analysis|Procedure: Perspective: Cross-
Cancer Institute
Weight Loss biopsy Sectional
(NCI)

Laboratory Assay in
Wake Forest
Determining Cancer Other: immunological diagnostic
University|National
280 NCT00899496 Resistance in Patients With Recruiting method|Other: physiologic 48 9-May-09 Jul-05 10-Mar-10 Jun-09
Cancer Institute
Metastatic Cancer and in testing
(NCI)
Healthy Participants

Genetic: DNA methylation


analysis|Genetic: in situ
hybridization|Genetic:
microarray analysis|Genetic:
Tumor Angiogenesis in reverse transcriptase-
National Cancer
302 NCT00898729 Patients With Endocrine Completed polymerase chain 400 9-May-09 Jan-07 7-Oct-09 Nov-08 Sep-09
Institute (NCI)
Tumors reaction|Other:
immunohistochemistry staining
method|Other: laboratory
biomarker analysis|Procedure:
biopsy

Vanderbilt-Ingram
Studying Biomarkers in Cancer
Genetic: protein analysis|Other:
282 NCT00900003 Patients With Pancreatic Recruiting Center|National 9-May-09 May-07 11-Aug-09 Oct-08 May-12
laboratory biomarker analysis
Cancer Cancer Institute
(NCI)

46 of 47 4/20/2010, 8:16 PM
Pancreatic Cancer - Clinical Trials

Primary
Enrollmen First Completion Last Last
Rank NCT ID Title Recruitment Interventions Sponsors Phases Study Designs Start Date Completion
t Received Date Updated Verified
Date

Genetic: fluorescence in situ


hybridization|Genetic:
polymerase chain University of
Cancer-Related Protein
reaction|Genetic: protein Michigan Cancer
Biomarkers in Blood and Active, not
276 NCT00900094 expression analysis|Other: Center|National 4350 9-May-09 16-May-09 Jul-07
Tumor Tissue of Patients recruiting
immunohistochemistry staining Cancer Institute
With Cancer
method|Other: laboratory (NCI)
biomarker analysis|Other: mass
spectrometry

Other: medical chart


review|Other: questionnaire
Nurse-Provided Care or administration|Procedure: Beckman Research
Standard Care in Treating fatigue assessment and Institute|National Primary Purpose: Health
286 NCT00902733 Recruiting 125 14-May-09 Jul-08 23-Jun-09 Jun-09 Jul-13
Patients With Pancreatic management|Procedure: Cancer Institute Services Research
Cancer psychosocial assessment and (NCI)
care|Procedure: quality-of-life
assessment

Genetic: gene expression


Study of Previously analysis|Genetic: microarray
Collected and Stored analysis|Genetic: mutation
Tissue Samples From analysis|Genetic: polymerase
Enrolling by National Cancer
251 NCT00904514 Patients Previously chain reaction|Other: flow 241 16-May-09 Oct-07 16-May-09 Mar-08
invitation Institute (NCI)
Enrolled in a Completed cytometry|Other:
National Cancer Institute immunoenzyme
Clinical Trial technique|Other: laboratory
biomarker analysis

Studying Pain and Other: medical chart


Symptom Distress in review|Other: questionnaire Beckman Research
Patients With Advanced administration|Other: study of Institute|National
197 NCT00950144 Recruiting 123 30-Jul-09 Dec-08 30-Jul-09 Jul-09 Apr-11
Colon Cancer, Rectal socioeconomic and demographic Cancer Institute
Cancer, Pancreatic Cancer, variables|Procedure: quality-of- (NCI)
or Liver Cancer life assessment

Study of Blood Samples


From Patients With
Genetic: protein All Ireland
Malignant Melanoma,
analysis|Genetic: proteomic Cooperative
270 NCT00974610 Metastatic Breast Cancer, Recruiting 300 9-Sep-09 Aug-08 9-Sep-09 Sep-09 Oct-10
profiling|Other: laboratory Oncology Research
Advanced Lung Cancer,
biomarker analysis Group
Pancreatic Cancer, or
Colorectal Cancer

47 of 47 4/20/2010, 8:16 PM